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SUMMARY 
 
There are various preparations of Sutherlandia frutescens commercially available on the market, 
the quality and consistency of which have not been scientifically investigated. 
 
The overall aims of this project were to assess the pharmaceutical quality and consistency of 
commercially available solid dose Sutherlandia frutescens containing products (viz. tablets & 
capsules) by exploring the use of monitoring the pharmaceutical presentation, flavonoid profile 
and antioxidant activity levels and to develop/or adapt methods and specifications that may be 
used for the quality control of such products.  
 
Seven solid dose Sutherlandia frutescens containing products (SCP) were purchased from 
various stores around the Western Cape and included in this study.  The physical appearance, 
information on the packaging, the presence and content of the package insert, the organoleptic 
properties of the dosage form of the selected products were assessed as a means to determine the 
possible compliance of the products with regulatory requirements.  
 
Total phenol concentrations of each of the SCP were analyzed using the Folin-Ciocalteu reagent 
assay.  Antioxidant tests were conducted on all the SCP using two assays, viz ferric reducing 
antioxidant power (FRAP) and diphenyl picrylhydrazyl (DPPH). Chromographic fingerprints of 
all of the SCP were generated using high performance liquid chromatography (HPLC) to identify 
and isolate individual flavonoids.  Fractions of these flavonoids were collected and further 
analyzed using LC-MS to confirm identification of compounds.  
 
Stability tests were conducted on all of the selected SCP.  The products were stored under 
elevated temperatures and environmental humidity conditions and total phenol, antioxidant and 
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chromatographic analysis was conducted on these samples.  Samples of each of the SCP were 
hydrolyzed using HCL and then analyzed using HPLC to test the stability of the flavonoids 
present in each product.     
   
The SCP investigated in this study physically appeared to be of quite good “pharmaceutical” 
quality, but generally lacked information on the date of manufacture and lacked package inserts, 
or when these were present they contained insufficient information. 
 
All the SCP had antioxidant activity which ranged, in descending order as follows: Promune® >> 
Big Tree 350® >> Sutherlandia Pinnacle® > Sutherlandia Health Connection Wholefoods® > 
Bio-Sutherlandia® > Big Tree Pro® >>Phyto Nova SU1®.  The two assays used i.e. ferric 
reducing antioxidant power (FRAP) and diphenyl picrylhydrazyl (DPPH) were useful in 
comparing the relative potencies of the selected SCP.  The SCP capsules possessed greater 
antioxidant power than the tablets.  
 
The total phenol concentration of the selected SCP varied from 4.162 to 13.930 mg gallic acid 
equivalence,  in descending order: Promune® >> Big Tree 350® >> Sutherlandia Pinnacle® > Big 
Tree Pro® > Phyto Nova SU1® > Sutherlandia Health Connection Wholefoods® > Bio-
Sutherlandia®, which correlated with the antioxidant activity results.  
 
All the selected SCP contained the flavonoids, sutherlandins A to D in varying amounts.  The 
SCP capsules having far greater sutherlandin levels than the tablet dosage form. The 
chromatographic fingerprints generated were compared to existing data.  The peaks that 
resembled sutherlandins A to D were collected and sent for mass spectrometry analysis to 
confirm their identity. 
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Elevated temperature and humidity significantly affected the aesthetic, pharmaceutical quality 
and the chemical stability of the SCP.  The SCP appeared to be particularly affected by the 
elevated humidity, which caused a decrease in the total phenol content of the products. 
 
The SCP are very susceptible to acid hydrolysis. Under these conditions the 4 sutherlandins are 
significantly degraded to derivatives of quercetin and kaempferol, which in turn are also 
susceptible to acid hydrolysis but not to the same extent. 
 
Based on the results obtained, it is recommended that, the manufacturers of SCP pay more 
attention to the information provided on the package inserts and the storage conditions for their 
products.  Further the levels of antioxidant activity, total phenols and flavonoid (sutherlandins A 
to D) be used as specifications to control the quality of commercially available solid dose 
Sutherlandia frutescens containing preparations on an individual basis. 
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pter 1 
 
INTRODUCTION 
indigenous to 
mnwele” (Van, 
ation and viral 
diseases (Rood, 1994, Humphries et al., 2006) as well as a supportive treatment for anxiety, convulsion, 
depression, hot flushes and irritability during menopause (Gericke et al., 2001; Mills et al., 2005; Prevoo 
g S. frutescens 
leaves, similar 
ially available 
ge forms, namely tablets, capsules, tinctures, creams, gels and herbal teas. The quality and 
consistency of these commercially available phytomedicinal preparations are however not known nor 
easily verifiable.  
rdes (2006) in 
the guidelines 
anufacturing 
ished product 
must comply with packaging, labelling and regulatory requirements set by the South African Medicine 
Control Council (MCC). Bandaranayake (2006) defines the term, “quality” as the status of a drug that is 
determined by identity, purity, content, chemical, physical, and biological properties, or by the 
manufacturing processes. Upon reading the packaging labels of current commercially available S. 
frutescens (Sutherlandia) preparations, the names of the products and manufacturers are often visible and 
Cha
 
Sutherlandia frutescens (Fabaceae/Leguminosa) is a traditionally used phytomedicine, 
South Africa (Fu et al., 2008). It is commonly known as “cancer bush”, “kankerbos” and “u
Wyk, 1997) and is used or claimed to be useful in the treatment of internal cancers, inflamm
et al., 2004; Ojewole, 2008). The most commonly used ethnomedicinal method of preparin
for treatment of internal disease is by making a hot water extract from the dried twigs and 
to preparing a tea (Humphries et al., 2006). Sutherlandia is however increasingly commerc
in various dosa
 
Many factors determine the quality of herbal products. As briefly discussed by Kroll and Co
order to have a high quality product of an individual herbal species one must comply with 
for Good Agricultural Practice (GAP) during the cultivation of the plant, as well as Good M
Practice (GMP) standards during the manufacture of the final product. In addition, the fin
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re in fine print 
and expiry dates are not always present.  Often, package inserts or information regarding the chemical 
constituents, possible side-effects, dose recommendations and physical appearance (e.g. white tablet) 
none of these 
uthority of all 
at the present commercially available 
herbal products are of good pharmaceutical quality, safe for use and effective.  
The quality of the commercially available Sutherlandia preparations can be judged on the levels of its 
et al., 2005).  
plants. These 
 
tawodi, 2004; 
Fernandes et al., 2004). Flavonoids may therefore be responsible for, or contribute to most of the 
therapeutic properties which Sutherlandia is claimed to possess and should thus be good markers to use 
flavonoids are 
eparation as a 
nt preparation 
tal phenol levels could be 
estimated using tests such as the Folin-Ciocalteu reagent technique (Singleton et al., 1999). The profile 
and levels of flavonoids and the total polyphenol content of Sutherlandia, and the factors which may 
influence their levels in the finished herbal product have however not yet been fully studied.   
 
easily identifiable. The treatment or claimed therapeutic uses are frequently given somewhe
found in synthetic pharmaceutical products are omitted in herbal preparations. Moreover 
products are registered with the Medical Control Council (MCC) which is the regulatory a
medicines available in South Africa. Thus there is no guarantee th
 
chemical constituents. Sutherlandia frutescens is said to contain gamma (γ)-amino butyric acid (GABA), 
D-pinitol, L-canavanine, triterpenoids, and flavonoids (Gericke et al., 2001; Mills 
Flavonoids are water-soluble polyphenols and over 4000 have been isolated from 
compounds are good free radical scavengers (Kondo et al., 1999; Chu et al., 2000; Hsu et al., 2005) and as
such, may be used to prevent inflammation and for the treatment of tumours and cancers (A
when monitoring the quality of commercially available Sutherlandia preparations. Since 
polyphenols, one could simply measure the level of total polyphenols in the Sutherlandia pr
measure of their quality.  Individual flavonoids (glycosides and aglycones) present in the pla
can be assayed using high performance liquid chromatography (HPLC), while to
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 on the levels 
of activity they should possess. For example, as for many other herbal preparations Sutherlandia is 
expected to have antioxidant activity (Atawodi, 2005). The antioxidant activity of the Sutherlandia 
veral tests are 
lhydrazyl is a 
freely accepts 
ouration from 
assay is the ferric reducing antioxidant power (FRAP) assay (Benzie et al., 1996). The use of the level of 
antioxidant activity to compare the quality of Sutherlandia product has however, to our knowledge, not 
re the use of 
al quality and 
consistency of commercially available solid dose Sutherlandia frutescens containing products (viz. tablets 
& capsules) and to develop/or adapt methods and specifications that may be used for the quality control of 
cribe the quality and regulatory compliance of selected representative solid dose 
 To determine the total phenol and flavonoid levels of selected commercially available solid dose 
Sutherlandia products, 
 To determine the profile and levels of specific flavonoids in the selected Sutherlandia products, 
 To determine the levels of antioxidant activities of the selected Sutherlandia products,   
The quality of commercially available Sutherlandia preparations can perhaps also be judged
preparations may be quantified from their ability to scavenge free radicals. For the latter se
available, one being the diphenyl-2-picrylhydrazyl radical (DPPH) assay. Diphenyl-2-picry
stable organic free radical with an absorption range between 515-528nm, and one that 
electrons. When DPPH accepts an electron it loses its absorption ability, and a visual discol
purple to transparent/yellow is observable (Hsu et al., 2005). Another colourimetric antioxidant activity 
yet been employed. 
 
Given the afore mentioned arguments, the overall aims of this project were to explo
monitoring flavonoid profile and antioxidant activity levels to assess the pharmaceutic
such products.  
 
The specific objectives of the study were:    
 To assess and des
Sutherlandia-containing products,   

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uced (or acid-
induced) degradation on the flavonoid profile and levels and the antioxidant activities of the selected 
Sutherlandia products, and 
ate quality control specifications that may be used for the selected Sutherlandia 
 
dia frutescens are subjected to quality 
ated temperature, humidity and acidity;  
 The antioxidant activity will decrease, 
 Total flavonoid and polyphenol levels may decrease or remain unchanged, 
ocussed on the quality of commercially available pharmaceutical solid dose S. 
frutescens containing products and the use of antioxidant activity, total and free flavonoid levels to assess 
the quality of such products.  
 To determine the effect of temperature, environmental humidity and chemical-ind
 To formul
preparations.  
 
It was hypothesized that when solid dosage forms of Sutherlan
transforming conditions such as elev
 Levels of  flavonoid glycosides will decrease and 
 Levels of free aglycone flavonoids will decrease. 
The present study thus f
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Figure 1: Flowering Sutherlandia 
frutescens plant.  
 (Xaba, 2003)  
 
pter 2 
 
LITERATURE REVIEW 
2.1. Introduction 
cription of the 
plant, its traditional uses, dosage forms and the known phytochemicals. A discussion on the flavonoids, 
methods used to evaluate antioxidant activity, quality control of herbal preparations as well as the 
am se Sutherlandia products are also included. 
 
Sutherlandia frutescens (L.) R. Br. is a member of the Fabaceae/Leguminosa 
family (Rood, 1994; Van Wyk et al., 1997; Roberts 1990; Manning, 2003). It 
 height of 
ng leaflets 
3). These 
n
in  to m
summer (September to December), they are orange-red in colour and are 
carried in short racemes in the leaf axils at the tips of the branches. Large, 
bladder-like, papery inflated seed pods that are almost transparent (Xaba et 
al., 2003) are also present (figure 1). 
 
 
 
This chapter provides an overview of the Sutherlandia frutescens herb, focusing on the des
par eters used to assess quality of solid do
2.2   Sutherlandia frutescens the plant 
 
is a small perennial woody shrub, which grows to the approximate
1meter. The leaves are pinnately compound made up of small oblo
that are rounded at the tips (Van Wyk et al., 1997; Manning, 200
leaflets have a silvery appearance but are essentially grey-gree
with fine hairs on the top surface. The flowers bloom in spr
 in colour 
g id-
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us to the dry 
regions of South Africa and mainly distributed in the Western Cape and the Karoo regions of South Africa 
(Van Wyk et al., 1997; Fernandes et al., 2004). Due to the popularity of Sutherlandia amongst different 
ethnic groups, it is known by many different names, some of which are listed in table 1.   
 
mm rlandia frutescens amongst different ethnic outh Africa 
Sutherlandia frutescens, also known as Lessertia frutescens (Van Wyk 2008), is indigeno
Table 1: Co on names of Suthe  groups in S
Language Common name/s Reference 
English “Duck plant”, “Cancer Bush”, “Bladder Senna”
et balloon pea” 
 and the (Humphries 
“Scarl
et al., 2006; 
Manning, 2003) 
Afrikaans “Kankerbos”, “Blaasb
keurtjie”, “Klapp
ossie”, “Blaas-ertjie”, ”Eendjies”, 
ers” and “Hoenderbelletjie”  
(Katerere et al., 2005; 
Xaba, 2003) “Gansie
Tswana “Phettola”  
North-Sotho   “Lerumo-Lamandi”     
Sotho “Motelepe”  
Ancient Zulu “Insiswa” (Gericke et al., cited 2008) 
Xhosa/Zulu    “Umnwele” (Xaba et al., 2003) 
 
ernal cancers, 
 treatment of 
et al., 
2001; Mills et al., 2005; Prevoo et al., 2004; Ojewole, 2008). Sutherlandia is regarded as an 
immunomodulator since it appears to have the ability to regulate the immune system in chronic 
se (Gericke et 
s, tablets and 
capsules. However, the most commonly used ethnomedicinal method of preparing S. frutescens for 
systemic use is by making a hot water extract from the dried twigs and leaves, similar to preparing a tea 
(Humphries et al., 2006). Moreover, S. frutescens prepared in this way has been shown to possess reactive 
oxygen species (ROS) scavenging abilities (Fernandes et al., 2004; Atawodi, 2005). 
 
The medicinal uses for Sutherlandia are very diverse and include the treatment of int
inflammation and viral diseases (Rood, 1994; Fernandes et al., 2004). It is also used in the
anxiety, convulsion, depression, as well as hot flushes and irritability during menopause (Gericke 
inflammatory diseases e.g. osteoarthritis, rheumatoid arthritis and inflammatory bowl disea
al., 2001; Mills et al., 2005; Prevoo et al., 2004; Humphries et al., 2006). 
Sutherlandia frutescens is used in a variety of medicinal dosage forms e.g. gels, cream
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otein α-amino 
acid, L-canavanine which is said to have anti-tumour and antiviral activity that may serve as a marker in 
the treatment of HIV/AIDS (Fernandes et al., 2004; Humphries et al., 2006). Other chemical actives of the 
 cachexia 
gamma-amino 
re also present 
sutherlandins, 
ost plants that possess antioxidant properties (Fu et al., 2009; 
Mills et al., 2005). 
 
l., 2006) 
enerally 
ur
the phenyl rings having a variety of functional groups (i.e.
iffering only in their type 
of bonds (de Sousa et al., 2008). The position of the functional 
rent functions 
Over 4000 flavonoids have been identified to date in different higher and lower plant species and it is 
estimated that 2% of all carbon photosynthesized by plants is converted into flavonoids which makes them 
excellent marker compounds to detect in plants (Marinova et al., 2005; Vijayakumar et al., 2008). These 
compounds are widely distributed in plants and add important sensory value, i.e. colour, flavour and 
Sutherlandia frutescens contains many active compounds. One such compound is the non-pr
plant include pinnitol, which is used traditionally as an anti-diabetic and in the treatment of
(Fernandes et al., 2004 and Humphries et al., 2006), while small amounts of saponins, 
butyric acid (GABA), asparagine and triterpenoid glucosides, known as sutherlandiosides, a
(Gericke et al., 2007). In addition, S. frutescens also contains flavonoids, in the form of 
which are well known constituents of m
2.3 Flavonoids 
 
Flavonoids are water soluble polyphenols (Roura et a
with a characteristic structure, as illustrated in figure 2. G
the chemical architecture is based on a three ring struct
such as hydroxyl and carboxylic groups. Flavonoids exist as free 
aglycones, and as O- or C-glycosides, d
e, with 
 R1-R6) 
Figure 2:  Chemical stru
general flavon
cture of a 
oid 
aglycone.   
 (Lai et al., 2006) 
groups helps to distinguish between the different flavonoids and contributes to their diffe
(Lai et al., 2007).       
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een shown to 
demonstrate anti-inflammatory and anti-tumorial properties (Lai et al., 2007). Plant flavonoids are usually 
bound to a sugar molecule, in the form of glycosides, which allows for several combinations of sugar(s) 
classes, namely 
flavonols, flavones, anthocyanidins, catechins and flavanones as illustrated in figure 3 (Fang et al., 2007). 
 
 
y detection or 
he HPLC and 
t in an extract 
ic fingerprints 
can be used to identify and isolate individual flavonoids (Lai et al., 2007; Germanỏ et al., 2006). Alkaline 
and acid hydrolysis may be used to release bound phenolic acids (flavonoids with sugar moieties attached) 
before these chromatographic tests are conducted (Germanỏ et al., 2006). While providing excellent 
information, these methods however require expensive and sophisticated equipment and much simpler 
cost effective methods may be worth considering.   
fragrance, as well as nutritional value (Li et al., 2006) among others. Flavonoids have b
for a single aglycone (Harborne, 1973). These flavonoids are further divided into five sub-
Figure 3: The sub-classes of flavonoids.  (Merken et al., 2000) 
Various methods may be used to quantify the levels of phenols and flavonoids in plants. These include: 
high-performance liquid chromatography (HPLC), liquid chromatography with diode arra
atmospheric pressure chemical ionization/mass spectrometry (i.e. LC/DAD-APCI/MS). T
LC/DAD-APCI/MS methods generate chromatographic fingerprints of compounds presen
which is detected either by diode array or fluorescence detectors and these chromatograph
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One method used to identify total phenols (total flavonoids) from natural products is known as the Folin-
Ciocalteu Reagent (FCR) assay (Roura et al., 2006). The first phase of the FCR assay consists of making 
 a purification 
easurements in 
tandard Folin-
974, where a 
and then the concentration of total phenols in the unknown solution established from the absorbance 
rms of gallic acid equivalence (Singleton et al., 1999). It is also 
t to note that different phenolic compounds show different colorimetric responses when using 
polyphenolics 
with one another and other components present in an extract may contribute to the overall antioxidant 
activity, thus antioxidant activity cannot be predicted solely on the basis of total phenolic content 
(Amarowicz et al., 2004). 
 
 the 
accumulation of reactive oxygen species (ROS), especially in chronic inflammatory diseases such as 
asthma, Alzheimer’s disease, inflammatory bowel disease (IBD), rheumatoid arthritis (RA), atherogenesis 
and diabetes mellitus (Atawodi, 2005). The accumulation of ROS can be lessened by using antioxidants 
which displace electrons that contribute to chronic inflammatory diseases. 
up a liquid filtrate of the material or substance which is to be evaluated. This is followed by
step which removes all sugars and organic acids that may contribute to the absorbance m
the FCR assay (Li et al., 2006). In the final phase of the assay, one would follow a typical s
Ciocalteu assay protocol such as the one developed by Wildenrant and Singleton in 1
standard curve of total phenol concentration versus absorbance is constructed using gallic acid as standard 
readings of the gallic acid solutions, in te
importan
FCR (Amarowicz et al., 2004).  
  
Different classes of phenolics are likely to have varying antioxidant strengths, synergism of 
2.4 Antioxidants and their purpose 
 
There is a considerable amount of evidence that suggests that cellular damage arises from
 
 
 
 
 10
 
Inflammation is one of many specific immune responses induced by the innate immune system, which 
only provides early defence against pathogens that invade the body. It is characterized by an increase in 
ukocytes and 
 immune cells 
ory explosion, 
xygen species 
lammatory 
cascades which cause subsequent tissue damage. It is apparent that ROS does this through the up-
et al., 
e genes is the 
 and adaptive 
Kaplan et al., 2006; Verma, 2004). By interacting with or by reducing the 
accumulation of ROS e.g. with use of antioxidants, the immune and inflammatory response can thus be 
significantly modulated.  
 
ntroduced into 
ssessing anti-
 used to treat 
een suggested 
cing apoptotic 
cell death, a group of structurally diverse antioxidants should be capable of inhibiting NF-κB activation 
(Kaplan et al., 2006; Dirsch et al., 1998). Given the potential usefulness of the antioxidant activity of S. 
frutescens it would thus be desirable to quantitate the levels of such activity in the different solid dose 
SCP and explore the methods which may be used to do so.  
 
blood flow and permeable vasculature, which increases the accumulation of fluid, le
inflammatory mediators, i.e. cytokines, to the injured tissue (Feghali et al., 1997). When the
are activated, they accumulate and penetrate into the tissue where they undergo a respirat
resulting in an increase in their oxygen use, an increase production of cytokines, reactive o
(ROS), and other inflammatory mediators. The ROS produced can initiate and continue inf
regulation of a number of different genes involved in immune and inflammatory response (Kaplan 
2006). One such ever-present transcription factor that may be implicated in regulating thes
nuclear transcription factor-kappa B (NF-κB), whose primary role is to regulate the innate
immune responses (
Most antioxidants which are non-enzymatic defences against the accumulation of ROS are i
the body via our diets (Berker et al., 2007). A variety of herbs have been identified as po
inflammatory and antioxidant properties, among them, S. frutescens. These herbs are often
inflammatory disorders including those caused by excessive accumulation of ROS. It has b
that since oxidants are capable of activating nuclear factor κB (NF- κB) involved in indu
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 a ity     
 
There are many methods that can be used to determine the antioxidant activity of herbal products. They 
chemoluminescence of neutrophils and the ferric reducing antioxidant power (FRAP).  
avengers that 
 phenols 
can be tested based on their ability to scavenge the stable diphenylpicrylhydrazyl (DPPH) free radical (Li 
zed water as a 
tract at 515nm 
illiams et al., 
nm decreases 
when/if the extract is able to reduce the stable DPPH (Li et al., 2007; Brand-Williams et al., 1994). The 
advantages of using the DPPH test are that one can see a visual change in colour when a reaction has 
detect active 
nt activity test is one that focuses on luminol and lucigenin enhanced 
chemoluminescence of neutrophils stimulated with L-formyl-L-methionyl-L-phenylalanine (FMLP) and 
can also be used in in-vitro studies (Fernandes et al., 2004). This test is however very time consuming and 
requires a lot of precision. 
 
2.5 Methods used to evaluate antioxidant ctiv
include methods based on measuring radical scavenging, luminol and lucigenin enhanced 
 
Sutherlandia contains flavonoids and phenols which are able to act as free radical sc
terminate radical chain reactions during triglyceride oxidation. Thus the antioxidant activity of
et al., 2007). The free radical DPPH test method is commonly used to determine the ability of flavonoids 
to transfer hydrogen (H) atoms to radicals (Tsimogiannis et al., 2006). Using distilled deioni
standard, one measures the absorbance of the antioxidant activity of DPPH by the crude ex
(Li et al., 2007), which is the ideal wavelength to measure DPPH absorption (Brand-W
1994). A visual colour change from purple to yellow is observed and the absorbance at 515
- 
occurred, one can evaluate many samples in a short period and it is sensitive enough to 
ingredients at low concentrations (Hsu et al., 2005).   
 
A second antioxida
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. In this assay 
changes in absorbance of test mixtures at 593nm are monitored and compared to that for mixtures 
containing known concentrations of ferrous ions (Benzie et al., 1996). This assay measures the reduction 
3+  Fe2+) in the 
ar to Prussian 
 1998; Amarowicz et al., 2004; Hadi et al., 2004). This method is also 
very simple, inexpensive and convenient. 
The one disadvantage of using the DPPH and FRAP antioxidant tests to assess herbal products is that one 
in the herbal preparation that 
contributes to the action. Thus further tests, e.g. HPLC fingerprinting, etc, to identify the phenolic 
po
 
ions 
 
Sutherlandia frutescens s, such 
as gels and creams which are topically applied to the skin, tonics, tablets and capsules which are 
rn society it is 
iversally 
accepted standard parameters and validated procedures (tests) by which the herbal remedies, especially 
traditionally used herbal remedies, can be tested. There are many websites and health shops which can be 
visited either electronically or physically to purchase S. frutescens containing products which are claimed 
to have miraculous healing abilities, ranging from treating mild asthma to being an immune modulator.  
A third test for antioxidant activity is the ferric reducing antioxidant power (FRAP) assay
of ferric-tripiridyltriazine (TPTZ) to ferrous iron (Fe /Ferricyanide complex to Ferrous
presence of antioxidants with a notable change in absorbance and colour from yellow/cle
blue or shades of green (Cao et al.,
 
cannot assess the direct effect of a specific chemical compound present 
com und responsible for the free radical scavenging must be conducted. 
2.6 Quality of commercially available Sutherlandia frutescens preparat
 containing products are commercially available in a variety of dosage form
consumed orally, and the dried herb/plant material which can be made into a tea. In mode
important that such products are of acceptable quality, safety and efficacy for consumers. 
 
It is however extremely difficult to assess the quality of these preparations since there are few un
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s but few who 
actually test whether, or provide evidence that, their claims of efficacy are true. As a result of this lack of 
scientific research on the identification, quality and effects of all (or even just some of) the active 
tescens products by their manufacturers, these products will not generally qualify as 
registered medicines.    
he registration 
satisfy the MCC standards and regulations pertaining to safety, efficacy and quality (Mander, 1998). 
ore many 
 standards set 
nd standards are 
available to ensure quality of traditional herbal and natural food supplements. Such guidelines may be 
cts could also be assessed.  
 
2.6.1   Parameters to assess quality of solid dose Sutherlandia products 
enced by the 
 2006) as well 
ltural Practice 
such as the Food and Drug Administration (FDA) of the USA, the European Agency for the Evaluation of 
Medicinal Products (EMEA), and the Therapeutic Goods Administration (TGA) of Australia to mention a 
few, are available to help establish the quality of herbal products. These guidelines set standards for the 
cultivation and manufacture of herbal and other pharmaceutical preparations and provides information 
There are many companies which invest a lot of money in producing these herbal remedie
ingredients in S. fru
 
At a national level, the Medicines Control Council (MCC) plays a vital role in regulating t
of any medicines produced in South Africa. Any products sold with a stated medical purpose have to 
These regulatory standards are very time consuming and costly to comply with and theref
indigenous herbal “medicines” can only be traded as remedies because they have not met the
by the MCC for registration as medicines. At an international level a few guidelines a
used to identify tests and criteria on which the quality of Sutherlandia produ
 
As mentioned in chapter 1, the variability of the medicinal value of a plant can be influ
different conditions of growth, harvesting, drying and storing of the material (Gulati et al.,
as how it is manufactured and packaged. Thus, various guidelines such as Good Agricu
(GAP) and Good Manufacturing Practice (GMP) and the guidelines from various regulatory authorities, 
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 the European 
Union (EMEA, 2006), some of the parameters that could be used to assess the quality of indigenous herbal 
products such as Sutherlandia, are as follows:   
1 names, part of plant used, origin, 
2 of collection, time of harvest, stage of 
3.  Raw Materials (specifications should follow preset standards, quantitative tests that should be 
d and specific 
ion criteria which includes; 
physiochemical properties, biological actives, formulation methodology and storage conditions),  
6.   End product (dosage form for consumption and stability data should be included), and  
7 tions (the standards on which the scientific quality, quality 
control/assurance and appropriate use can be guaranteed.  Such specifications should comply with 
ncentrating on 
Since no Sutherlandia frutescens preparations have thus far, mainly due to insufficient available scientific 
evidence, been approved by the MCC, this thesis aims to investigate the feasibility of evaluating the 
quality and consistency of selected Sutherlandia-containing products based on their antioxidant activity, 
total phenol and flavonoid levels. The results obtained could convince the MCC that sufficient scientific 
pertaining to a variety of parameters that has a bearing on product quality.  As established by
 
.  Botanical source (i.e. identity, scientific and common 
contamination, and which part of the plant is most toxic),  
.  Growth conditions (GAP, whether wild or cultivated, site 
growth, storage conditions, as well as pre- and post- harvest treatments),  
conducted to determine constituents relevant to the plants significance and stability data should be 
recorded),  
4.  Processes applied to the starting material (extraction process, solvents, method use
precautions that should be followed),  
5.  Botanical preparations (established standardization, purity and specificat
.  Herbal product specifica
existing standards, with human safety data given top priority and non-clinical tests co
toxicology (Gulati et al., 2006)).      
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 their products 
are of suitable quality to be classified as a medicine.   
data on at least these parameters should be available if a manufacturer wishes to claim that
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pter 3 
 
PLAN OF WORK 
3.1  Introduction 
aceutical quality 
of commercially available solid oral dosage forms of Sutherlandia frutescens are presented. 
 
nd antioxidant 
 commercially available tablets 
and capsules of Sutherlandia frutescens and to develop or adapt methods and specifications that may be 
used for the quality control of such products. 
s and describe the quality and regulatory compliance of selected representative solid dose S. 
tal phenol levels of selected representative solid dose S. frutescens-containing 
products,   
 To determine and compare the antioxidant activity of selected commercially available solid dose S. 
frutescens products, 
 To determine the profile and specific flavonoids in the above mentioned products, 
Cha
 
 
In this chapter the objectives of, and the approach used in this study to assess the pharm
3.2  Objectives of study 
 
The overall aims of this project were to explore the use of monitoring flavonoid profile a
activity levels to compare the pharmaceutical quality and consistency of
 
The specific objectives of the study were: 
 To asses
frutescens-containing products,   
 To compare the to
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environmental 
humidity and chemically-induced (or acid-induced) degradation] on the selected products, and 
 To formulate quality control specifications that may be used for the selected Sutherlandia frutescens 
preparations. 
3.3  Study Approach 
entioned objectives the following were done: 
  
3.3.1  Selection and collection of commercially available solid dose Sutherlandia containing 
select number 
bility of any 
Sutherlandia-containing solid dose preparations. Products listed on the internet which appear to be 
available in more than one province in South Africa as well as exported internationally will be included in 
proximately 5 tablet and 5 capsule preparations were 
to be purchased and included in this study.  It was postulated that this sampling procedure and sample size 
the most frequently used and 
whose ongoing quality would be an important consideration.  
3.3.2  Assessment of regulatory compliance of selected Sutherlandia dosage forms 
 
Although at present there are no regulatory processes by which herbal preparations are formally registered 
in South Africa it can still be assumed that the physical appearance of herbal dosage forms, the quality of 
 To determine the effect of various environmental stresses [i.e.  elevated temperature, 
 
 
To realize the above m
products 
 
In order to establish what S. frutescens containing products were commercially available, a 
of local pharmacies, health stores and supermarkets were visited to access the availa
this study if they are readily available. From this, ap
would best represent the Sutherlandia solid dose preparations that would be 
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 preparations 
should, as for normal pharmaceuticals, be useful as indicators of the quality and possible regulatory 
compliance of such herbal preparations. Thus, in this study the physical appearance of, information on the 
 of the dosage 
products were to be assessed as a means to determine its possible compliance with 
regulatory requirements.  
ent 
and herbal medicine, the following regulatory compliance items on which the quality assessment could be 
 
1. tion would be 
ould serve its 
ch as sunlight and 
humidity.  Also allows for opening and re-sealing of the product. A safety seal (tac seal) should be 
fully intact on all newly purchased products to ensure that the product has not been tampered with.  
e. The product 
 stipulated on 
s should be available in 
each of the selected S. frutescens containing products. The colour, texture and odour are also 
important. Uniformity of weight and size of each preparation would be another factor to consider. 
4. Package insert: The information contained on the insert should comply with set guidelines. 
 
The above items and criteria were selected on the basis that they would probably be part of the set criteria 
required by most regulatory authorities and would be the minimum to which any Sutherlandia-containing 
the packaging and labeling of the preparation and any information that accompanies such
packaging, the presence and content of the packaging insert and the organoleptic properties
form of the selected 
 
Upon reading the criteria which the EU has established when differentiating between a herbal supplem
based were selected.  
 Physical appearance of the packaged preparation: e.g. the container choice of selec
plastic or amber glass securitainers with snap-on or screw-on caps. The containers sh
function of protecting the product from deterioration by environmental conditions su
2. Label: The labeling should be clear and visible. All printed information should be legibl
name, manufacturer, composition, an expiratory date and storage conditions should be
the label. 
3. Product: At least one month’s supply (approximately 30) of tablets or capsule
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ucted on any 
Sutherlandia-containing product it had to meet the set criteria recorded in appendix A1.  
 
3.3.3 Comparison of total phenol content of the dosage forms 
heir activities, 
S. 
ay be due 
to inclusion of other plant materials or even synthetic molecules. Consequently, the Folin-Ciocalteu test 
 containing 
olin-Ciocalteu 
 hydrochloric 
 visual colour 
s study it was 
intended to conduct the FCR test using smaller quantities than usually prescribed so that the assay could 
be done on a 96well microplate and in so doing allow many samples to be tested simultaneously. Finally, 
l levels of the 
 is a popular 
s standards to 
eparation and 
d per unit weight was covered. Gallic acid is a phenolic 
unit in tannic acid from oak galls, it is inexpensive, water soluble, easily recrystallized from water, readily 
dried and is stable in the dry form (Singleton et al., 1999) and was thus deemed suitable for use in this 
study.    
product of acceptable quality should comply. Thus before any tests were to be cond
 
Sutherlandia, like most plants, are rich in polyphenols which probably also contribute to t
especially antioxidant activity. The level of polyphenols will not specifically indicate the quality of 
frutescens containing products, but will only indicate the presence of other polyphenols which m
was used to measure the total polyphenol levels of each of the selected solid dose Sutherlandia
products, using gallic acid as standard. This test offered several advantages. Firstly, the F
Reagent (FCR) which consists of sodium tungstate, sodium molybate, distilled water and
acid (Singleton et al., 1999), can be purchased already mixed. Secondly, the test is quick, a
change from intense yellow to green/blue occurs when phenols are added. Thirdly, in thi
because the identity of all the phenols in the plant material was not known the total pheno
plant materials were to be expressed in terms of gallic acid equivalents. Gallic acid
comparison standard used to test total phenol content. Historically tannins were first used a
test total phenol content in wines and spirits, however due to the varying methods of pr
origins of tannins, too wide a range of colour yiel
 
 
 
 
 20
 
3.3.4  Determination and comparison of antioxidant activity of the dosage forms  
 
ect. While the 
ant activities 
o prevent the 
t only indicate 
capable of giving an antioxidant activity which may be due to the inclusion of other plant material or even 
. frutescens is 
rnandes et al., 
unds such as 
flavonoids (phenolics) which possess antioxidant activity (Marinova et al., 2005) and are the compounds 
of interest in the present study. Thus it was decided, for the antioxidant tests, to use aqueous extracts of 
a preparation.  
 
FRAP) assays 
ys.  
The DPPH test is based upon observing an antioxidant’s ability to transfer hydrogen atoms to a stable 
DPPH free radical (Tsimogiannis et al., 2005; Molyneux, 2004). The reduced DPPH can be observed by a 
visual decolourization from purple to transparent or yellow which can be further analyzed by testing the 
absorbance using UV detectors (Molyneux, 2004). The popular standard used in the DPPH assay is 
ascorbic acid (vitamin C) (Molyneux, 2004), but since S. frutescens contains flavonoids that are known 
Herbal medicines, as for conventional medicines, are taken for some or other therapeutic eff
exact therapeutic effects of Sutherlandia are not known it is expected to have antioxid
(Atawodi, 2005). Antioxidants have gained popularity particularly for their ability t
detrimental effects that free radicals have on the human body. Antioxidant activities will no
the quality of S. frutescens containing products, but will also indicate the presence of molecules that are 
synthetic molecules.   
 
Although the products to be tested were solid dosage forms it was noted that indigenously S
usually consumed orally as a hot water infusion to treat internal ailments such as cancers (Fe
2004; Humphries et al., 2006). Such teas are expected to contain water-soluble compo
the solid dosage form of the Sutherlandia that more closely mimic the traditional te
In this study the diphenylpicrylhydrazyl (DPPH) and ferric reducing antioxidant power (
were used because these tests are less expensive and more robust than other antioxidant assa
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for the present 
study.  In addition, with a slight modification of the existing assay (Singleton et al., 1999) the DPPH assay 
could also be converted to a micro-plate assay, with the added advantages of speed of analysis and 
creased reproducibility.  
ferrous iron 
le change in 
arowicz et al., 
2004; Hadi et al., 2004). As has been done in previous plant studies (Molyneux, 2004) ascorbic acid was 
 terms of 
ascorbic acid equivalents. This assay was also conducted on a multi well micro-plate which allowed for 
lt ncy of colour development. 
 
 
Flavonoids are present in S. frutescens and thus must also be in products of Sutherlandia, and contribute to 
parations can 
s used.  
romatographic 
products. The method used was to be based, with a few modifications, on the analytical method used by 
Avula, et al. (2010). HPLC allows for the separation of compounds present in the aqueous extracts of S. 
frutescens, and indicates individual compounds as peaks in the chromatogram that can be further analyzed 
by observing the purity of such peaks at different wavelengths and by collecting them via a fraction 
antioxidants the use of the flavonoid, quercetin, was considered as a better positive control 
in
     
The FRAP assay measures the reduction of ferric-tripiridyltriazine (TPTZ) to 
(Fe3+/Ferricyanide complex to Fe2+/Ferrous) in the presence of antioxidants. A notab
absorbance and colour from yellow/clear to Prussian blue is observed (Cao et al., 1998; Am
used as a positive control in this study and the product’s antioxidant activity expressed in
simu aneous analysis as is required by the strict time depende
3.3.5 Determination of the flavonoid profile of the dosage forms  
the activity, and thus quality, of such products. The qualitative flavonoid levels in such pre
thus be used to monitor and compare the quality of such products, provided a reliable assay i
 
In this study high performance liquid chromatography (HPLC) was used to obtain ch
fingerprints of compounds present in, and thus the flavonoid profile of, the aqueous solutions of the 
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r using mass 
spectrophotometry. The HPLC method offered a sensitive, quick and accurate means to determine the 
flavonoid profiles of the different product and allowed comparison with previous (i.e. Avula et al., 2010) 
findings.  
3.3.6 ermination of the effect of temperature and humidity on the stability of the dosage 
forms 
Although some of the Sutherlandia solid dosage forms that are commercially available have expiry dates 
idity are the 
the stability of 
 subjected to 
fter tested for 
d. Accelerated 
stability tests are routinely recommended for conventional pharmaceutical products (Lieberman et al., 
1998) and herbal products (Ababalle et al., 2008; EMEA, 2006) and the results used to determine shelf-
lives, expiry dates, etc. Ideally such stability tests should be based on the level(s) of specific or select 
i ity of using total phenol 
and antioxidant levels was to be investigated as potential alternate methods.   
 
The Sutherlandia products contain constituents such as flavonoid glycosides, etc. that are expected to be 
sensitive to acid hydrolysis. Depending on the degree of susceptibility to acid the various solid dosage 
form products may vary in their release of active compounds in acidic environment (e.g., stomach) leading 
collector connected to the HPLC system and thereafter analyzing the fractions furthe
 
Det
 
it is unclear how those dates or shelf-lives have been determined. Since temperature and hum
main factors that could affect the stability of herbal products the effect of these factors on 
the different Sutherlandia products were investigated. For this the products were to be
ambient and elevated temperature and humidity (in climatic chamber) conditions and therea
total phenol and antioxidant activity and the results obtained for the products compare
chem cal constituents but this was not to be done in this study. Instead, the viabil
 
3.3.7 Determination of the effect of acid hydrolysis on the stability of the dosage forms  
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n be expected 
from the dosage form. In this study the hydrolysis of the products by hydrochloric acid was to be assessed 
as another means to compare the quality of the various products. Thus the HPLC fingerprints of the 
 were assessed to compare the relative stability of the products. 
3.3.8  control specifications that may be used for the selected 
Sutherlandia frutescens preparations  
In order to determine the specifications which can be used for quality control specifications of SCP the 
results of the above mentioned assays (DPPH, FRAP, FCR and HPLC) were used. 
to variable absorption and bioavailability and, consequently, variable in vivo effects that ca
unhydrolysed and acid hydrolyzed products
  
 Determination of the quality
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pter 4 
 
METHODS AND PROCEDURES  
cted solid oral 
ed under the 
lity-indicating 
properties of selected Sutherlandia frutescens solid dosage forms, determination of antioxidant activity of 
the dosage forms, determination of total phenol content of the dosage forms, determination of the 
 the dosage forms, determination of the effect of temperature and humidity on the 
stability of the dosage forms, determination of the effect of acid hydrolysis on the stability of the dosage 
ms 
4.1 Chemicals, materials and equipment 
y: 
taining products
Cha
 
In this chapter the methods and procedures used to assess the quality and consistency of sele
dose Sutherlandia frutescens containing products are presented. The information is arrang
following sub-headings: Chemicals, materials and equipment, determination of qua
flavonoid profiles of
for and data analysis.  
 
 
4.1.1 Chemicals and materials 
 
The following chemicals and materials were used in this stud
 Commercial solid dose Sutherlandia con  (see figure 4 in results section),  
 Distilled water (distilled using a Fi-streem 2901 manufactured in England),  
dical powder 2.2-diphenyl-1-picrylhydrazyl (DPPH), free ra  (Sigma, D9132, USA),  
 methanol (analysed grade, Saarchem, 4116408ME, South Africa),  
  gallic acid (Purum, Fluka, 48630, Switzerland),  
 sodium carbonate (general purpose reagent, BDH Chemicals Ltd., 30121, England ),  
 Folin-Ciocalteu Reagent (Sigma-Aldrich, 47641, USA),  
 quercetin dehydrate (HPLC grade, Sigma, 085K0720, USA),  
 ethanol (analysed reagent, KIMIX, 09665 27706, South Africa),   
 ascorbic acid (99% pure, Saarchem, 1022315, South Africa),  
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 formic acid (analysed reagent, Saarchem, A/7A570484, South Africa),  
  acetonitrile (HPLC grade, Honeywell. Burdick & Jackson, 10071743, USA),  
 nitrogen (99.95%, AFROX, 8007258270508, SA),  
 dimethyl sulfoxide (Grade 1, Sigma, D-5879, Germany),  
 sodium acetate anhydrous powder (99%, Analytical reagent),  
 glacial acetic acid (analysed reagent, Merck, 1021020LC, South Africa ),  
 hydrochloric acid 32%(HCL) (analytical reagent, Saarchem, 1028782, South Africa),  
 2,4,6-tri[2-pyridyl]-s-triazine (TPTZ) (puriss ≥99%, Fluka, 93285, Switzerland),  
 iron (III) chloride hexahydrate (FeCl 3) (reagent grade, Sigma, 035K0180, USA),  
 helium (99.95%, Afrox, 8007258, South Africa). 
 
4.1.2 Equipment 
 
The following equipment was used in this study: 
 balance  (Adventurer OHAUS, Model AR2140, USA),  
 centrifuge (Heraeus Sepatech, Labofuge 200, West Germany),  
 vortex (Scientific industries, G-560E, USA),  
 micro-plates (Nunclon 96well plate),  
 spectrophotometer (Labsystem, Labsystem Multiskan ® MCC/340, Finland),  
 hot plate (Heidolph, model 50301, Germany),  
 grinder tubes (15ml Screw cap plastic test tubes),  
 digital thermometer (French Cooking -50°C to 200°C/-58°F to 392°F, France),  
 micro-pore filter paper (47mm filter membrane hydrophilic 0.45µm PVDF, Millipore Millex-HV),  
membrane filters 47mm, 0.45µm hydrophillic polypropylene  (Pall corporation,  66548 ),   
 syringes (10ml Sterile Syringe for single use, 060830),  
 recorder (Epson Quiet colour upgradeable LX-300 printer),  
 micropipettes and tips, mortar and pestle, epindorf tubes,  
 paper (A4 white sheets of paper),  
 beakers (glass of various sizes),  
 glass graduated measuring cylinders of various sizes,  
 high performance liquid chromatography (HPLC) apparatus   
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mp (G1311A, 
, Germany), 
lyte fraction collector (G164C, Germany), and the 
(Agilent 1200 system consisting of; degassing system (G1322A, Japan), quaternary pu
Germany), auto loading sampler (G1329A, Germany), TCC (G1316A, Germany), column C18 column 
15cm X 46mm, 5μm (Discovery, BL6357 HS, USA), diode array detector (G1315B
fluorescence detector (G1521A, Germany), ana
Agilent ChemStation software G2173-60101L, Germany),  
 climatic chamber (Labcon, FSIE-H2O humidity, L17030, South Africa),  
 filtration system; vacuum pump (ABM diaphragm vacuum pump, serial number 174089
tubing, Erlenmeyer flask (1000ml Millipore), side arm glass filter (Millipore, positioned
1095), rubber 
 above 
ced above the glass filter (Millipore approx. 250ml), Erlenmeyer flask), Volumetric cup which is pla
metal clip (Millipore, 1004703),  
 pH meter (Thermo Orion 2000, 074012, USA),  
 hot water bath (Gefran 500, 09/700, Italy),  
 desiccator (2atc, Gepruft, Germany),  
 magnetic stirrer and hot plate (Fried electric, MH.4, Israel)  
 thermo hygrometer (Tinytag TH-2500, Gemini Data Loggers, UK) 
 LC-MS system (Waters API Q-TOF Ultima, Netherlands). 
*** 
 
 
 
In order to determine the set objectives the following methods were used;  
sage forms 
Local pharmacies and retail outlets were visited between March and July 2008 and various internet sites 
searched to identify commercially available, oral solid dose Sutherlandia-containing products (SCP). 
Eventually, 7 SCP that were readily available were selected, purchased and included in this study. For 
each selected SCP the product name, supplier, package description, manufacturer, organoleptic properties, 
 
4.2 Methods and procedures 
 
4.2.1 Determination of quality-indicating properties of selected Sutherlandia solid do
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is information 
was used to make an assessment of the pharmaceutical quality of the preparations. 
4.2.2 Determination of antioxidant activity of the dosage forms  
d-Williams et 
Berker, et al., 2007) tests were used. The precise methods used 
are briefly described in the next few paragraphs. 
0ml methanol 
olic standard 
 appropriately 
diluted with methanol to obtain several standard solutions. These standard solutions were used to 
determine the free radical scavenging ability of quercetin and ascorbic acid over the concentrations ranges 
blished from 
H and 150µl 
amples of the 
as read on a 
ese wavelengths were chosen because they were 
commended in the 
literature (Li et al., 2007; Brand–Williams et al., 1994). The absorbance readings were recorded and used 
to calculate the percentage inhibition using the following equation:  
  Percent inhibition (%) = [(A0-AS) / A0] x 100    equation 1. 
dosage form, unit dose weight and presence or absence of package insert was tabulated. Th
 
 
To determine antioxidant activity of the SCP two popular techniques, viz. the DPPH (Bran
al.., 1995; Molyneux, 2004) and FRAP (
 
4.2.2.1 The di-phenyl-picryl-hydrazyl (DPPH) test  
 
First, a 20μM DPPH working solution was made by dissolving 7.88mg DPPH powder in 2
which was stored in an amber bottle in a refrigerator set at 2ºC until analysis. Methan
solutions of quercetin dihydrate (1mg/ml) and ascorbic acid (0.176mg/ml) were made and
of 1.5-10µg/ml and 0-176µg/ml, respectively. These concentration ranges were esta
preliminary experiments. Each designated well on the micro-plate received 50μl of DPP
methanol, quercetin or ascorbic acid standard solutions at various concentrations. All s
standards were run in triplicate. After 30 minutes the absorbance of each well w
spectrophotometer at 540nm and 492nm wavelengths. Th
the closest filters that the plate reader had to the recommended 515nm and 528nm, re
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he absorbance 
of DPPH with the vehicle (distilled water or methanol).  
 
follows. If the 
pestle. For the 
was placed in 
e vortexed for 
another 2minutes, centrifuged at 3500rpm for 10minutes and the supernatants pipetted into clean 
ion (for up to 
 a series of 6 
 each product. 
g/ml; product 
2, 0 to 18mg/ml; product 3, 0 to 20mg/ml; product 4, 0 to 12.5mg/ml; product 5, 0 to 1.5mg/ml; product 6, 
0 to 6mg/ml and product 7, 0 to 6mg/ml.  For the assay 100μl DPPH working solution followed by 100μl 
absorbance of 
gs at these 2 
lotted versus 
ating more than 
50% inhibition and/or the best linear regression fit of the data was then used, i.e. data recorded at 540nm. 
The inhibitor concentration at which 50% DPPH had been scavenged (IC50) was then interpolated from 
the selected curve for each SCP and this value used to compare the antioxidant powers the various SCP.   
Where (As) = the absorbance of DPPH with the sample (ascorbic acid or quercetin), (Ao) = t
To determine the radical scavenging ability of the SCP’ aqueous extracts were made as 
product was in a tablet form they were first ground into a fine powder using a mortar and 
capsule products the powder contents were used as such. For each product, 1g of powder 
marked grinder tubes (designated 1 to 7), 10ml of boiled distilled water added, the mixtur
2minutes, sonicated for 35minutes, allowed to steep for approximately 2hours, thereafter re-vortexed for 
correspondingly labelled grinder tubes. The concentration of each product’s aqueous extract was then 
taken as being 100mg/ml and these were stored in the freezer at -18°C until examinat
9months). The aqueous extracts of the SCP samples were thawed and diluted to obtain
concentrations within a suitable concentration range which was previously determined for
The ideal free radical inhibition concentration ranges were found to be: product 1, 0 to 15m
diluted product aqueous extract was added to the respective wells. After 30minutes, the 
each well was measured at 540nm and 492nm wavelengths. The absorbance readin
wavelengths were used to calculate the percentage inhibition and the latter values p
concentration for each SCP.  The better of the 2 curves at 540 and 492nm i.e. the one indic
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P) assay 
 
Firstly, a 300mM acetate buffer was made by dissolving 1.55g sodium acetate in 8ml acetic acid and 
nd was stored 
ng 25ml HCL 
 10mM TPTZ 
 FRAP test a 
3  
The FRAP reagent was made by placing 30ml acetate buffer into a amber vile to which  3ml FeCl3.6H2O 
solution, 3ml TPTZ solution and 6ml distilled water were added. A fresh solution of FRAP reagent was 
ive control a 1mM ascorbic acid stock solution was made by dissolving 8.8mg powder in 
50ml distilled water and used to prepare standard solutions ranging from 0 to 0.176mg/ml in 
concentration.   
 
Generally the 100mg/ml aqueous extracts of the SCP (see 4.2.2.1) were too concentrated to use as such in 
s found to be 
say was conducted on a 96well micro-plate where 25µl of the test sample, water or ascorbic 
acid was pipetted into individual wells, 200µl FRAP reagent  added and, after a 10minute development 
period, the absorbance at 540nm wavelength measured on a multi-scan spectrophotometer.  Each test was 
run in triplicate. 
 
4.2.2.2 The Ferric Reducing Antioxidant Power (FRA
diluting it with distilled water up to a volume of 500ml. The acetate buffer had a pH of 3.6 a
at room temperature over a period of 1 month. A 40mM HCL solution was made by mixi
with 175ml distilled water. Using 3ml of the 40mM HCL and 0.0093g TPTZ powder a
solution was made which could be stored in a fridge for up to two weeks. On the day of the
fresh solution of 20mM FeCl was made by dissolving 54mg iron (III) chloride in 10ml distilled water. 
made on the day of analysis.  
 
For the posit
the FRAP test but after several dilution tests the ideal concentration for each product wa
15mg/ml.  This concentration was then used in the FRAP test. 
 
The FRAP as
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s constructed 
using  GraphPad Prism 5 , the line of best fit obtained by least squares linear regression (r2=0.9961) and 
from this the ascorbic acid equivalents (AAE) of the SCP were calculated using the absorbance values 
. The AAE for each SCP was tabulated and used to compare the 
antioxidant activity of the various SCP. 
4.2.3 Determination of total phenol content of the dosage forms  
To determine the total phenol content of the selected SCP the Folin-Ciocalteu reagent (FCR) assay (Roura 
ium carbonate 
ht to the boil, 
4 added, the solution was allowed to stand for 
24hours, thereafter filtered and distilled water added to the filtrate to make up a volume of 500ml. This 
solution was stored in a sealed bottle in a cool dark cupboard until use. 
 GA in 10ml 
 parafilm and 
y, calibration 
the GA stock solution. Two hundred micro-litre of each solution was added to the micro-plate well, 10μl 
FCR and 30μl NaCO4 added, and after a 2hr plate development period the absorbance was read at 690nm 
wavelength. The results were used to construct a standard curve of the GA concentrations versus 
A standard curve of the 540nm absorbance versus concentration of the ascorbic acid wa
®
obtained for the individual SCP
 
 
et al., 2006) was conducted. 
 
The first requirement in conducting a total phenol test using FCR was to make up a sod
solution as follows:  25g anhydrous sodium was dissolved in 100ml distilled water, broug
allowed to cool to room temperature, a few NaCO crystals 
 
For the positive control a stock solution of gallic acid (GA) was made by dissolving 0.5g
ethanol which was then diluted with distilled water to 100ml. The flask was sealed with
stored in the refrigerator until needed or discarded after 2days. At the time of the assa
solutions of GA over the concentration range of 0 to 18.750mg/ml were made by appropriately diluting 
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d to determine 
the total phenol concentration of each solid dose SCP in terms of gallic acid equivalents (GAE).  
 
tract solutions 
se absorbance 
ion versus 690 
andard curve. Finally, the GAE values obtained were used to compare the total phenol 
content for the SCP.  
vonoid profile of the dosage forms a high performance liquid chromatography 
(HPLC) technique was used to create chromatographic fingerprints of compounds present in the aqueous 
 
The HPLC method of Avula et al. (2010), with a few modifications, was used to generate the 
of 100mg/ml 
LC apparatus 
 0.45µm pore 
mn (Supelco, 
itrile 
(solvent A) and 0.1% formic acid in distilled water (solvent B) and a flow rate of 1.000ml/min and the 
following gradient: 85% [B] and 15% [A] to 35% [B] and 65% [A] over a 20min period, each run was 
followed by a 100% [A] wash phase of 10mins and a 5min equilibration period, giving a total run time of 
absorbance from which an equation (y=mx+c) was extrapolated by linear regression and use
To determine the total phenol content of the SCP, 200μl of 1.875mg/ml SCP’ aqueous ex
were added to 10μl FCR and 30μl NaCO4 and the absorbance at 690nm obtained. Using the
values the GAE for each individual SCP were obtained from the gallic acid (GA) concentrat
nm absorbance st
 
4.2.4 Determination of flavonoid profile of the dosage forms  
 
To determine the fla
solutions of the products. 
chromatographic fingerprints. Briefly, 50μl of 100mg/ml aqueous solution and 50µl 
methanol extracts of each SCP was injected into the Agilent HPLC system (see 4.1.2 for HP
used). Before injection the solutions were filtered using a syringe and micro-pore filters of
size. Separation of the various plant constituents was achieved on a reverse phase C18 colu
15cm X 46mm, 5μm) operated at 20ºC. The mobile phase consisted of 0.1% formic acid in aceton
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a 260nm and 
360nm wavelengths. 
 
® P Compaq® 
ingerprints for each SCP was inspected and the retention times and 
heights of all the SCP peaks present recorded. 
 
inspected and peaks that occurred at retention times between 8.5mins to 20mins, and eluted over a 0.5mins 
were injected 
 seen in the 
 400nm using 
e subjected to 
liquid chromatography mass spectrometric (LC-MS) analysis to confirm whether these fractions were 
sutherlandins or not. The LC-MS was conducted on a Waters API Q-TOF Ultima LC-MS instrument, the 
% acetonitrile 
, (2.1x50mm) 
 
used to effect 
t A decreased 
linearly to 0%, from 6mins to 8mins solvent B remained at 100% and at 8.01mins the system was re-
equilibrated to 100% solvent A until the end of the run time. The following detection conditions were 
used:  source ESI+, capillary voltage set at 3.5kV, cone voltage 35, RF1 40, source temperature 100°C, 
desolvation temperature of 350°C, desolvation gas flow 350 L/h and cone gas flow 50 L/h. 
 
35mins, were used. A diode array detector was used to detect the eluted compounds at 
Data acquisition was performed by the ChemStation  software operated on a H
microprocessor. The chromatographic f
 
To identify some of the peaks the chromatographic fingerprints of the methanolic extract of product 5 was
period with a threshold greater than 17.8mAU’s were individually collected using the fraction collector 
(G1364C Analyt). The collected fractions were divided into 2 batches: batch 1 fractions 
onto the HPLC column using the same gradient as described above and each peak
chromatographic fingerprint was tested for peak purity and spectral profile over 180nm to
the DAD and ChemStation® software facilities of the HPLC. The batch 2 fractions wer
injection volume of the samples were 2μl (diluted 10 times with 1ml 0.1% formic acid 50
using an ultrasonic bath for 20mins prior to injection), the column a Waters BEH C18
reverse phase column while the mobile phase consisted of solvent A: water and B: acetonitrile, with a
flow rate of 0.35ml/min, and a run time of 15minutes. The following solvent gradient was 
the peak separation: at 0mins to 0.5mins solvent A was 100%, from 0.5mins to 6mins solven
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ompared with 
data existing in the literature to identify the isolated compounds. 
 
4.3.1 rmination of the effect of temperature and humidity on the stability of the dosage 
forms  
uality of the selected SCP, the products 
First, to ascertain whether elevated environmental temperatures (40°C to 45°C) and humidity levels (70% 
 a make-shift 
red regularly. 
us solution of 
 the desiccator 
was sealed with silica gel and the entire desiccator then placed in a hot water bath where the temperature 
was maintained at 45ºC. The relative humidity and temperature inside this chamber was monitored daily 
 this chamber; 
osed” samples 
 this chamber. 
d and visually 
idity-tight containers on 
the quality of the SCP. The original intention was also to measure and compare the total phenol level, 
antioxidant activity and flavonoid profile (as described in 4.2.2 to 4.2.4) of the 2 sets of samples (Sealed 
and exposed groups) but this was not done (see results and discussion 5.2.5.4). 
 
The mass to charge ratio (m/z) for each peak in the collected fractions was recorded and c
Dete
 
To determine the effects of temperature and humidity on the q
were exposed to ambient and elevated temperature and humidity conditions. 
to 79% RH) could induce gross physical changes in SCP stored exposed and sealed (i.e. enclosed in 
package), samples of each product were stored (for 7 to 21 days) under varied conditions in
chamber and the organoleptic features of the tablets, capsules and capsule powders monito
The make-shift climatic chamber consisted of a desiccator in which a saturated aqueo
sodium chloride was placed to create a stable humidity of 75% (Rockland, 1960). The lid of
using a thermohygrometer (TinyTag). Two sets of samples of the products were placed in
the batch “Sealed” samples were placed in air- and water-tight containers while the “Exp
were placed in plastic containers open and exposed to the controlled climatic conditions of
The samples in the chamber were monitored every 2days and at the end of the 14day perio
checked for organoleptic changes to determine the effect of storage in air-and hum
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eft exposed to 
ambient environmental conditions in a petri dish on a bench top in the laboratory and monitored over a 
2month period. The ambient temperature ranged between 18°C to 28ºC and the relative humidity was 
 in individual 
and a relative 
 and humidity 
s (Ambient & 
 
Aqueous extracts of the samples were prepared as described in 4.2.2 and analyzed for total phenol level, 
nditions were 
 student t-test 
l significance of any change in the antioxidant activities 
(measured as IC50 or mg/ml AAE), total phenol levels (measured as mg/ml GAE) and flavonoid levels 
 
ms  
, that may be 
 susceptibility 
ay thus be a 
useful criterion on which the quality of such SCP can be compared (esp. since this may affect in an acidic 
environment (e.g. stomach) the conversion of glycosides to aglycones etc. and complement the release of 
active compounds from the products leading to variable absorption and bioavailability and, consequently, 
variable in vivo effects that can be expected from the dosage form). In this study the hydrolysis of the SCP 
For the main data 5 samples (n=5) of each intact SCP (i.e. intact tablet or capsule) were l
below 35%. A further quintuplet samples (n=5, designated Elevated group) were placed
snap-cap airtight transparent plastic containers in a climatic chamber maintained at 40ºC 
humidity of 70% for 14-days. The chamber was checked daily to verify the temperature
levels (i.e. machine digital display). The SCP samples stored under the two sets of condition
Elevated groups) were monitored twice a week and removed for tests after the designated 14-day period. 
antioxidant activity and flavonoid profile as described in 4.2.3 to 4.2.5. The data of the products stored 
under the 2 sets of conditions i.e. ambient and elevated temperature and humidity co
compared to determine the effect of temperature and humidity of the quality of the SCP. The
with p = 0.05 was used to determine the statistica
(peak heights) caused by the different storage conditions.  
4.3.2 Determination of the effect of acid hydrolysis on the stability of the dosage for
 
The solid dose Sutherlandia products contain constituents such as flavonoid glycosides
sensitive to acid hydrolysis and the levels of such susceptible compounds and the degree of
to acid may vary from product to product. Comparison of the acid stability of various SCPs m
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f the various 
products. Two milliliter of the 100mg/ml aqueous extract of each product was refluxed with 2ml of 0.6M 
HCL for 1hour at 80ºC in a water bath and left to cool overnight. The next day the solution was filtered 
were then re-
 section 4.2.5.  
r absence and 
 (see section 4.2.5) to determine the relative acid 
susceptibility of the various Sutherlandia containing products.  
, total phenol 
CP, the average and standard deviations were calculated 
and the student t test applied to determine whether differences were statistically significant with the level 
of significance being set at p equal to or less than 0.05.   
by hydrochloric acid was therefore assessed as another means to compare the quality o
and dried using nitrogen gas (Audu et al., 2007). The dried hydrolyzed sample residues 
suspended in 2ml distilled water, micro-pore filtered and analyzed by HPLC as described in
The chromatographic fingerprints obtained for each product was analyzed for the presence o
size of peaks suspected to be flavonoid compounds
 
4.4  Data Analysis 
 
To ascertain whether there were significant differences between the antioxidant activity
content and flavonoid levels for the different S
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pter 5 
 
RESULTS AND DISCUSSION 
5.1 Introduction 
 available S. 
frutescens products together with their antioxidant activity, total phenol, flavonoid levels and the effect 
that elevated temperature, environmental humidity and acid hydrolysis have on these properties are 
discussed. 
 
herlandia solid dosage forms 
In the period of March till the end of July 2008 there were 
approximately 22 products containing S. frutescens 
ps in the 
 4 were 
u
perties, d
of a pa
insert, to mention but a few) of these are recorded, in 
table 2, and assessed in order to establish and describe 
the quality and regulatory compliance of solid dose 
Sutherlandia-containing products (SCP) in general.   
 
 
 
In this chapter the findings on the regulatory compliance of the selected commercially
5.2.1 Regulatory compliance of the selected Sut
 
commercially available in pharmacies and health sho
city of Cape Town. Of these the 7 shown in figure
selected for inclusion in this study and vario
product name, manufacturer, organoleptic pro
form, dosage weight, supplier and presence 
s details (i  
osage 
ckage 
.e.
Figure 4: Selected Sutherlandia
containing products (SC
 frutescens 
P). Product 1: 
Bio harmony, Bio-Sutherlandia® tablets, 
2: Phyto Nova Sutherlandia SU1® tablets, 
3:Health Wholefoods Connection 
Sutherlandia® tablets, 4:Pinnacle 
Sutherlandia® tablets, 5:Adjuvant 
Promune® Sutherlandia Extract capsules, 
6:Big Tree Sutherlandia Pro® .capsules 
and 7:Big Tree Sutherlandia 350® 
l
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  aining products. 
 
 
Table 2: Quality indicating properties of selected commercially available solid dose Sutherlandia cont
PRODUCTS 
Quality Indicating 
Property or Item 
 
landia®
 harmony 
 
1 
® 
Phyto N
2 
rlan
th Wholefoods 
Suthe
Pinnac
Pr ® 
 
 
Tree 
6 
Sutherlandia 
350® 
Big Tree 
7 
dia® rlandia® BioSuther  
SU1Bio
Sutherlandia Suthe
Heal
Sutherlandia
ro® 
omune
Adjuvant le P
 ova Con Bignection   
4 53 
Batch number 1 0609SL03        0180 P1221 2 6E01113 52488 2894          022 020702 5316 
Package insert Absent Present Absent sAb ent Present Absent Absent 
White plasti
containe
c 
r with
transparent green 
screw-on lid. 
as
container with an 
orange screw-on securitainers and white snap-on cap. 
h
con  with a 
blue screw-on 
lid. 
W
securitainers and 
white snap-on 
c
 
ntainer with 
a white screw-
Transparent 
amber glass 
container with a 
black screw-on 
lid. 
 a 
White pl tic White W ite plastic tainer
hite White plastic
co
lid. ap. on lid.  
Lime green
on containe
black font 
image of
 lab
r w
and
 the top 
half of a golden 
een 
 
ellow 
gree
lack 
Stylized 
Sutherlandia 
plant image. 
 
 
Pale and 
label wit
navy and white 
print. 
el
ith
nd 
blem 
of a pinnacle, 
i.e. triangle on 
the top quarter 
of the label. 
Li
label with dark 
green, black and 
white print 
ch fades 
 
Stylized image 
of a lime green 
yellow tree on 
the top half of 
e label. 
White label 
which fades into 
green, with black 
font.  
 
Stylized image 
of a lime green 
yellow tree on 
the top half of 
the label. 
White label 
whi
el 
ith 
 
Y
with 
and b
 
label 
n, red   
print. dark blue 
h black, 
Y
w
a
and an em
low label 
 blue, white 
black print 
into light 
purple, with 
black and 
purple font.
 
 an
apple on a gr
background.
me-green 
th
Description of 
container & 
packaging 
n a 
me 
ing 
   
Enclosed i
with the sa
box 
   
colour
Amount in 
container 60 6 60 60 60 60 0 60 
Dosage form & 
 
Physical 
dimensions 
e
mm 
blet, Co
2mm 
41mm
Tablet, ro
T = 3mm
5m
Tab
n
=
 = 
 = 
C
S
D
1
00:  
Capsule 
Size 00: 
D = 7mm 
20mm long 
Tablet, Conv
round, 
D = 15
x- Ta
round, 
D = 12mm
nvex-
 D = 12m
und flat, 
m coD 
T = 2mm 
C = 41mm 
T = 
C =   C = 4
 
m TC
let, round 
vex, 
mm 
apsule 
ize 2: 
Capsule 
Size 013  = 5mm 
5mm long 
D = 10mm 
23mm long  2 mm 41mm 
Organoleptic 
properties 
Uncoated 
compound powder
tablets. 
 
 
 dark 
d yell
ted 
compound 
 tablets.  
green 
r wit
ct od
Uncoated
compound powder 
tablets. 
le-gray
our w
odour 
c
mpound 
powder tablets.  
 
Pale-bro
gree
with specks and 
a di
W
dark green cap,  
 
Whitish-gray 
fl
p
distinct odour 
 
 
Pale green 
th a 
Medium sized 
transparent 
casing, 
 
Light green fine-
fluffy-fibrous 
powder and a 
strong distinct 
odour.   
 Pale-green colour 
with fine
green an
specks with a faint 
ow 
colou
distin
odour 
Uncoa
powder
 
Pale- 
h 
our 
Pa
col
 
 Unco
 
-green 
ith faint 
oated hite body & 
Large sized 
transparent
casing,  
wnish 
n colour 
stinct odour 
uffy fine 
owder with a 
fluffy fibrous 
er wipowd
strong distinct 
odour. 
Date of 
Manufacture - - - - - - - 
Expiratory date  2011-04 - 2010-01 2009-02 2008-09 2009-10 2009-09
0.770 ±0.045 
5.8
0.516 ±0.003 0.608 ±0.014 
3% 
0.50
18 0.
0.567 ±0.033 0.406 ±0.036 
8.867% 
5 ±0.006 0.287 ±0.001 
348% 
Weight (g) 
44% 0.581% 2.30 1. 8% 5.820 RSD 
Dosage meals 
1-2 tablet(
daily with meals * 
1-2 
twice daily after 
mea  * 
2 capsules once 
daily after meals 
1capsule  twice 
daily  
1capsule twice 
daily * 
tablet(s) 
1 tablet daily * 1 tablet twicedaily after 
 s) twice 
ls
Constituents 
 
S. frutes
subspecies 
 herb. 
dicalcium 
phosphate, starch 
and Magnesium 
stearate 
tescens 
ies 
Microphylla 
SU1. 300mg 
Guar gum, 
magnesium 
stearate, 
microcystalline 
cellulose, starch 
(maize), sodium 
starch glycolate 
Sutherlandia     
300mg 
Sutherlandia     
300mg 
S. frutescens 
extract 90mg 
Microcystalline 
cellulose   120mg 
 
 
S. frutescens 
subspecies 
Microphylla 
SU1. 300mg 
 
S. frutescens. 
350mg 
 
cens 
S. fru
subspec
Microphylla
g 300m
Tableted with 
Key: 
* As recommended by a practitioner 
RSD Relative Standard deviation 
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products looked like typical conventional, registered and pharmaceutically acceptable dosage forms. The 
name of each product was clearly visible and all the products except Promune® Adjuvant were easily 
 to protect the 
y seals on all products were fully 
intact upon purchase which ensured that the products had not been tampered with.  
all the products contained details of the product name, manufacturer, composition, expiratory date and 
® product where an expiratory date was 
absent. None of the 7 products had any indication of a manufacturing date, this appears suspect since there 
g to 350mg 
per dosage form and generally the products were uniform in mass, having a relative standard deviation 
inistration 
 dosage was 
 the necessary 
 
composition, pharmacological classification, pharmacological action, indications, contra-indications, 
warnings, dosage and directions for use, side-effects and special precautions, known symptoms of 
overdose and particulars of its treatment, identification, presentation, storage instructions, registration 
 
The selected products comprised of 4 compressed powder tablets and 3 capsule preparations. All the 
identifiable as Sutherlandia-containing products. The packaging of the SCP clearly served
product from deterioration by environmental conditions and the safet
 
Besides the name, the rest of the label information of the SCP was clear, visible and legible. The labels of 
storage conditions except the Health Wholefood Connections
is no means on whether to test the reliability of the expiratory date.  
 
The amount of Sutherlandia frutescens contained within the selected SCP ranged between 90m
(RSD) less than 9%, an acceptable value that is well within the limit of the Food and Drug adm
(FDA) (Abballe et al.,  2008).   
 
Five of the seven products did not contain package inserts although the recommended
indicated some where on the packaging. When present the package insert did not contain all
information required of a registered drug. The required information should include: scheduling status, 
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ackage insert.  
Two of the package inserts only contained approximately 65% of this required information.  
 
th many of the 
 the physical 
rican Medical 
that is traded 
er, 1998).  
Herbal products such as the SCP investigated in this study are not yet formally included in this registration 
long period to 
 Sutherlandia-
ly little extra 
roduct quality 
criteria needed for their registration by the MCC. The MCC should thus insist that manufacturers of these 
SCP do the necessary tests, collect and provide the relevant information to confirm and assure the 
ceutical quality of the products and then apply for drug registration based on pharmaceutical 
quality. The inclusion of information from additional tests e.g. measurement of antioxidant activity and 
of the herbal 
In conclusion, the Sutherlandia-containing tablet and capsule dosage forms investigated in this study, 
physically appeared to be of quite good “pharmaceutical” quality, but generally lacked information on the 
date of manufacture and lacked package inserts, or when these were present they contained insufficient 
information.  It should however be feasible that present commercially available Sutherlandia-containing 
number, name and business address of applicant and, lastly, the date of publication of the p
Although not being registered most of the selected SCP aesthetically appeared to comply wi
specifications that would be set for a registered pharmaceutical product. In short, based on
assessment they appeared to be of quite good “pharmaceutical” quality. The South Af
Control Council (MCC) regulates any medicines with a stated or implicit medical purpose 
and produced nationally by setting standards regarding safety, efficacy and quality (Mand
process, mainly because the stated or implicit medical purpose of SCP is not yet clinically proven or 
scientifically accepted. The registering process is also complicated, expensive and it takes a 
satisfy all the set criteria (Marchetti et al., 2007). Nevertheless it should be feasible that the
containing tablet or capsule dosage forms investigated in this study could, with relative
information (e.g. stability data and validation of expiry dates, etc), easily meet most of the p
pharma
total phenol levels, etc. could even strengthen the evidence of pharmaceutical quality 
product.  
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roduct quality 
criteria needed for their registration by the MCC.    
 
 5.2.2 Antioxidant activity of the selected Sutherlandia products 
y two tests, viz., 
the diphenyl picrylhydrazyl (DPPH) scavenging and ferric reducing antioxidant power (FRAP) assays.  
5.2.2.1 The DPPH scavenging ability of SCP 
 
concentration 
s of quercetin 
ibition of the 
d 540nm after 
30mins, 45mins, and 60mins and calculating the percent inhibition of the DPPH absorbance. Sample 
 
n increased. A 
nce at 492nm 
% inhibition, 
tration range over which each of the selected SCP could be 
g/ml for 
product 2, 0 to 20mg/ml for product 3, 0 to 10mg/ml for product 4, 0 to 1.5mg/ml for product 5, 0 to 
6mg/ml for product 6 and 0 to 6mg/ml for product 7.  
The percent inhibition of DPPH absorbance produced by various concentrations of each of the SCP is 
given in tables A.3 to A.9 in appendix A. Figure 5, summarizes the results of these tables.  
solid dosage forms could, with relatively little extra information, easily meet most of the p
 
To compare the quality of the selected SCP their antioxidant abilities were determined b
 
Firstly the conditions for the test with regard to the reaction time, optimal wavelength and 
range for the various products to be tested were established. To do this, serial dilution
dihydrate or ascorbic acid were added to a methanolic solution of DPPH and the inh
scavenger monitored by observing the colour change, reading the absorbance at 492nm an
results of these experiments are recorded in tables A.1 and A.2, in the appendices. As the concentration of
the standard solutions increased, the DPPH absorbance decreased and the percent inhibitio
10mg/ml solution of quercetin produced a 52% and 71.9% inhibition of the DPPH absorba
and 540nm, respectively and 0.176mg/ml solution of ascorbic acid caused 57% and 33.1
respectively. From this data the ideal concen
tested against DPPH was established and was found to be 0 to 15mg/ml for product 1, 0 to 18m
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Generally, as the concentrations of SCP increased so too did the extent of their ability to scavenge DPPH 
®  by the green 
ent inhibition 
e gradient for 
ith maximum 
uch higher concentrations. The IC50, i.e. the concentration of the SCP at 
 
recorded in table 3. 
T ues (i.e. Concentration at which 50% of DPPH is scavenged) of commercially 
Figure 5: Percent inhibition of DPPH by various concentrations of SCP.  
free radicals (i.e. their inhibition of DPPH absorbance). Product 5 (Promune ), represented
line, had the steepest % inhibition vs. concentration gradient with the maximum perc
occurring at a relatively low concentration compared to that of the other SCP, while th
product 2 (Phyto Nova SU1®), represented by the grey line, had the lowest of the SCP, w
percent inhibition occurring at m
which 50% of the DPPH was reduced, was extrapolated from the graphs and the values obtained are
able 3: IC50 val
available SCP 1 to 7. 
IC50 of SCP 
Product IC50 conc.  
(mg/ml) 
1 landia®  6.90     Bio-Suther
2   SU1®  16.20   Sutherlandia
3    Health Wholefoods Connection Sutherlandia®  5.00 
4    Pinnacle Sutherlandia®   4.20 
5     Promune®   0.80 
6    Big Tree Sutherlandia Pro®.  8.20 
7     Big Tree Sutherlandia 350®   2.80 
Quercetin 5.765 
Ascorbic acid 0.219 
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5 (Promune®) 
having the lowest and product 2 (Phyto Nova SU1 ) the highest IC50. The lower the IC50 value, the greater 
the antioxidant power of that product. Thus the selected SC ng order of greatest to 
® ®  Pinnacle® > 
>Phyto Nova 
osage form the capsules seemed to possess a greater antioxidant power (and 
possibly potency?) than the tablets.   
5.2.2.2 The ferric reducing antioxidant power of SCP 
ve of varying 
ent at 540nm 
e FRAP-ascorbic acid reaction was from clear to 
Prussian blue, and the change in absorbance versus ascorbic acid concentration was linear over a 
concentration range of 0 to 100ug/ml with an r2 value of 0.9961.  
 Figure 6:   Standard curve of ascorbic acid concentrations versus absorbance at 540nm in the FRAP 
test  
The DPPH IC50 values for the 7 products ranged from 0.8 to 16.2mg/ml with product 
®
P ranged, in descendi
lowest antioxidant power, as follows: Promune  >> Big Tree 350  >> Sutherlandia
Sutherlandia Health Connection Wholefoods® > Bio-Sutherlandia® > Big Tree Pro® >>
SU1®. Moreover, in terms of d
 
 
For the FRAP test ascorbic acid was used as the control antioxidant and the standard cur
concentrations of ascorbic acid versus the absorbance of the reaction with the FRAP reag
obtained is given in figure 6. The colour change for th
FRAP test results of Ascorbic acid
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y = (5.440 ± 
0.1698) x + (0.1338 ± 0.009049) and the results obtained are shown in table 4. 
Table 4: ascorbic acid equivalents) of Sutherlandia containing products 1 to 7 as 
determined in the FRAP assay. 
The ascorbic acid equivalents (AAE) for each SCP was calculated using the equation, 
 
Antioxidant activity (in 
Antioxidant activity 
 (in Ascorbic acid equivalents (AAE)) Product 
AAE (mg/ml) 
1      Bio-Sutherlandia®  0.004508 
2      Sutherlandia SU1®  0.007265 
3       Health Wholefoods Connection Sutherlandia®  0.009717 
4      Pinnacle Sutherlandia®  0.014741 
5      Promune®  0.061433 
6      Big Tree Sutherlandia Pro®.   0.009839 
7      ®  0.029018 Big Tree Sutherlandia 350
 
Based on the FRAP test results (table 4) the SCP ranged in antioxidant activity, in descend
greatest to lowest AAE, as follows (and >> represents significance, where p>0.05):  Pro
Tree 350® >> Sutherlandia Pinnacle® >> Big Tree Pro® > Sutherlandia Health Connection W
® ®
test, and again the capsules had the highest activ
ing order from 
mune®>> Big 
holefoods® 
>> Bio-Sutherlandia  > Phyto Nova SU1 . This was the exact order that was obtained with the DPPH 
ity. The FRAP antioxidant activity results thus 
corresponded directly to that of the DPPH test, confirming that Promune® had the greatest antioxidant 
to Nova SU1® 
Although there are no product specific data available, Fernandes, et al. (2004), reported that hot water 
extracts of S. frutescens possessed significant antioxidant activity. The present results confirmed that such 
activity is also found in solid dose SCP. It is noteworthy that the Promune® capsule contains S. frutescens 
freeze dried extract and that it had the highest antioxidant activity compared to the other products (2 
ability of all the selected commercially available Sutherlandia containing products and Phy
the lowest.  
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. Overall the 
antioxidant activity results suggest that such tests may be useful to compare the relative potencies of SCP. 
 
5.2.3 Total phenol content of selected Sutherlandia products 
urve of gallic 
 figure B.1 in 
 the graph 
and then used to calculate the total phenol content, in terms of gallic acid equivalents (GAE), of the SCP 
as a whole product and in terms of the stated amount of S. frutescens contained in each product. The 
 
Table 5: age mass and ol concen C) of Suther g products 
capsules and 4 tablets) which contained the dried whole S. frutescens plant material
 
For the determination and comparison of the total phenol content of the SCP a standard c
acid concentration reacting with FCR versus absorbance at 690nm was constructed, see
appendix B. The equation y= (0.03757 ± 0.002156) x + (0.06127 ± 0.022035) was taken from
results obtained from this calculation are summarized in table 5. 
 Aver  total phen tration (TP landia containin
Product 
 
 
number and name 
Average  mass of  
unit dose 
 
(mg) (n=3) 
TPC in total Product  
Powder 
 
(mg *GAE) 
TPC per mg Sutherlandia 
frutescens in product 
 
(mg *GAE / mg) 
1  Bio-Sutherlandia® 770.43 ± 0.045 4.162 0.005 
2   Sutherlandia SU1® 516.00 ± 0.003 5.209 0.010 
3   Health Wholefoods Connection 608.17 ± 0.014 5.404 0.009 Sutherlandia® 
4   Pinnacle Sutherlandia®  ± 0.006 8.279 0.016 505.37
5   Promune® 225.2 ± 0.001 13.930 0.062 
6   Big Tree Sutherlandia Pro®. 439.87 ± 0.033 5.715 0.013 
7    Big Tree Sutherlandia 350® 309.93 ± 0.036 6.637 0.021 
 * GAE = gallic acid equivalent 
 
Product 5 (Promune®) had the greatest total phenol concentration of 13.930mg GAE per dose unit dose, 
compared to that of the other SCP which ranged between 4.162 to 8.279mg GAE. The Promune® also had 
the highest level of TPC in terms of the stated amount of the S. frutescens present in each SCP while the 
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aterial. Since 
Promune is made from a freeze-dried aqueous extract of Sutherlandia this extraction process most likely 
contributed to the high levels of TPC in this product compared to the other SCP which contained the 
whole dried plant material.   
s significance, 
> Phyto Nova 
 exactly 
with the antioxidant activity results for the selected SCP. The latter finding is however not unexpected 
ivity and TPC 
he TPC of the 
 of flavonoids, compounds that are known to have antioxidant activity but the 
identity of the exact compounds responsible for the antioxidant activity of the SCP was not pursued 
further in the present study.  
 
romatography 
ucted on the aqueous extracts of the SCP and the chromatographic fingerprints 
obtained for all the SCP are presented in figures 7 to 13. Separate individual flavonoid compounds were 
identified by the retention time and the UV spectrum of the peak and the levels of the flavonoids are 
determined by the peak heights. 
TPC per mg plant material for the other products ranged from 5 to 20μg/mg plant m
® 
 
Overall the SCP varied in total phenol concentration in descending order (and >> represent
where p≤0.05): Promune® >> Big Tree 350® > Sutherlandia Pinnacle® >> Big Tree Pro® 
SU1® > Sutherlandia Health Connection Wholefoods® > Bio-Sutherlandia®, which correlated
since many phenolic compounds contained in plants have been shown to have antioxidant activity 
(Kirakosyan et al., 2004; Li et al., 2006; Amarowicz et al., 2004). Both the antioxidant act
results thus gave a good indication of the relative potencies of the SCP. A great portion of t
SCP probably consisted
5.2.4 Flavonoid profile of selected Sutherlandia products 
 
To identify and compare the flavonoid levels in each of the SCP, high performance liquid ch
(HPLC) analysis was cond
 
 
 
 
Bio-Sutherlandia® 
 Figure 7: HPLC chromatogram of 100mg/ml aqueous extract of SCP 1.  
 
Sutherlandia SU1® 
 
Figure 8: HPLC chromatogram of 100mg/ml aqueo
 
us extract of SCP 2.  
 
Health Wholefoods Connection Sutherlandia®
Figure 9: HPLC chromatogram of 100mg/ml aqueous extract of SCP 3.  
 
 
Pinnacle Sutherlandia® 
Figure 10: HPLC chromatogram of 100mg/ml aqueous extract of SCP 4.  
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Promune® 
 Figure 11: HPLC chromatogram of 100mg/ml aqueous extract of SCP 5.  
 
 
Figure 12: HPLC chromatogram of 100mg/ml 6.  
 
aqueous extract of SCP 
 
Big Tree Sutherlandia Pro® 
Big Tree Sutherlandia 350® 
Figure 13: HPLC chromatogram of 100mg/ml aqueous extract of SCP 7.  
 
From the chromatographic fingerprints (figures 7 to 13) there is a clear pattern of four dominant peaks of 
compounds that are present in all the SCP. These peaks had average retention times of 10.48 ± 0.21, 11.41 
± 0.18, 13.62 ± 0.12 and 14.22 ± 0.11mins, but the peak heights varied between the different SCP as 
shown in table 6.   
 47
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Table 6: Retention times and peak heights of reoccurring peaks of the Sutherlandia containing products. 
Product Peak 1 Peak 2 Peak 3 Peak 4 
RT Height RT Height RT T Height Height R  
Name and number in  ( Fs) .) in.) (mAUFs) (m .) (mAUFs) min.) (mAU  (min  (mAUFs) (m
1  Bio-Sutherlandia®  10.0 .40 13 4 6.7 .98 71.700 52.70 11.03 52 .3 11 0 13
2 10.  1 .30 5 25.4 4.25 12.70   Sutherlandia SU1
®  54 29.40 1.47 19  13.6 0 1
3   Health Wholefoods 
Connection Sutherlandia® 10  .20 0 9. 4.30 96.20  .60 64.80 11.55 70  13.7  14 30 1
4   Pinnacle Sutherlandia®  10.  1 .10 3 9.1 4.24 74.4053 100.80 1.49 67 13.6  17 0 1
5   Promune®  10.57 170.50 11.52 233.00 9 6. 4.28  13.6  14 60 1 141.10 
6   Big Tree Sutherlandia Pr 10.5 11 .30 9 42.5 .28 32.70o
®. 8 10.80 .33 21 13.6 0 14
7   Big Tree Sutherlandia 350® 10.5  11 60 2   2 139.70 .47 118. 13.6 219.5 .23 123.600 14
Average 10.48 81.24 11.41 83.13 13.62 125.59 14.22 78.91
Standard deviation 0.21 58.45 0.18 74.14 0.12 70.36 0.11 46.11
%RSD 2.00  1.58  0.88  0.77 
 
 
 peak heights) 
ks at retention 
represented by the 4 peaks, and that the Promune® contained 2 extra compounds. The data also suggested 
ounts of the 4 peaks among the SCP could be quite substantial 
(93.67, 91.72, 88.43 and 91% respectively). In general the heights of the peaks in the fingerprints of the 
l with the total 
The spectral profile of each of the 4 peaks, plus the extra 2 identified in the chromatographic fingerprints 
of the Promune and other SCP were determined using the diode array detector and spectral analysis 
software of the HPLC system.  In addition, the 6 identified peaks were collected with a fraction collector 
and analysed by HPLC and the spectral profiles of 5 of the fractions are given in appendix E. The peaks 
(retention times of 10.51 ± 0.21, 11.53 ± 0.25, 13.32 ± 0.32, 13.74 ± 0.36, 14.41 ± 0.48 and 17.13 ± 
 
For product 5 (Promune®) three of the 4 peaks were far more dominating (i.e. had higher
than that for the other SCP and the fingerprint for this product also contained additional pea
times 13.294 and 16.991mins. This implies that the SCP contained varying amounts of the compounds 
that the extent of this variation in the am
Key 
RT= retention time  
capsule SCP were also higher than that for the tablet products, a finding that correlated wel
phenol and antioxidant level results.  
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ectral profiles 
(e.g. maximum absorbance between 200nm to 360nm). Indeed, these fingerprints had excellent purity and 
the spectra of each were similar, if not identical, to that of sutherlandins recorded by Avula et al. (2010). 
The results thus suggested that all of the peaks were those of flavonoids.  
hromatographic fingerprints and 
LC-MS data obtained are given in Appendix F and the results summarized in table 7.  
 
 
0.54mins (n=4)) appeared to be that of single compounds and had distinct flavonoid type sp
 
The isolated fractions were also subjected to LC-MS analysis and the c
HPLC  fraction #  
an in) d retention time ( m
Mass spect sitive ion H)+ ra po  (M + 
(m/z) 
1, 10.51 ± 0.21 609. 7 - 2 41.2 - 
2, 11.53 ± 0.25 609. 7 - 2 41.2 - 
3, 13.32 ± 0.32 609.2 - -  - 
4, 13.74 ± 0.36 593.2 725.2 726.2 - 
5, 14.41 ± 0.48 593.2 594.2 725.2 726.2 
6, 17.13 ± 0.54 593.2 - - - 
 
therlandin B, 
s 3 and 4 also 
ively. Thus the 
, 14.373 and 
are given in figure 14 and according to Fu et al. (2010) sutherlandin A (peak 1) is quercetin 3-O-β-D-
pylopyranosyl(1→2)-[6-O-(3-hydroxy-3-methylglutaroyl)]-β-D-glucopyranoside, sutherlandin B (peak 2) 
is quercetin 3-O-β-D-apiofuranosyl(1→2)-[6-O-(3-hydroxy-3-methylglutaroyl)]-β-D-glucopyranoside, 
sutherlandin C (peak 3) is kaempferol 3-O-β-D-xylopyranosyl(1→2)-[6-O-(3-hydroxy-3-
fragments (with > 30% ndance) in the collected HPLC 
romune® 
Table 7: The mass of the 
fractions of P
 abu
The positive ion mass of the main compound in fractions 1 and 2 was 741.2 which correspond to that of 
analytes 1 and 2 reported by Avula et al. (2010) and were identified as sutherlandin A and su
respectively. Fractions 4 and 5 had an m/z value of 725.2 which corresponded to the analyte
reported by Avula et al. (2010) and designated sutherlandin C and sutherlandin D, respect
HPLC collected fractions 1, 2, 4 and 5, with the retention times of 10.928, 11.969
15.040mins, could be identified as sutherlandins A to D, respectively. The structures of these compounds 
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 (peak 4) 
is kaempferol 3-O-β-D-apiofuranosyl(1→2)-[6-O-(3-hydroxy-3-
methylglutaroyl)]-β-D-glucopyranoside.  Moreover the other 2 
®  of 609.2 
y diglycoside derivatives of quercetin and 
kaempferol, respectively.    
at all the 
SCP contained 4 flavonoids (sutherlandins A to D) in 
osage 
forms were concerned the capsules again had far greater sutherla
 
5.2.5 Effect of elevated temperature and environmental humidity on the organoleptic features, 
antioxidant activity, total phenol content (TPC) and flavonoid profiles of Sutherlandia 
 elevated temperature and environmental humidity on the quality of the SCP were 
r a period of time under ambient and elevated temperature and 
flavonoid levels.    
  
First, to ascertain whether elevated environmental temperature (40°C) and relative humidity level (very 
high > 70% RH, medium = 55 to 70% (RH) and low < 55% RH) could induce gross physical changes in 
methylglutaroyl)]-β-D-glucopyranoside and sutherlandin D
prominent peaks in the Promune fingerprint are, with m/z
and 593.2, most likel
 
Collectively, the results of the present study thus showed th
amounts the levels of which can be quantified and used to compare 
the relative potency of each product. Finally, as far as the d
varying 
Figure 14: Schematic diagrams of 
sutherlandins A to D. (Fu, et al. 2010) 
ndin peak heights than that of the tablet 
dosage form, suggesting that the capsules had greater flavonoid potency.  
containing products. 
 
The effects of
determined by storing the products fo
humidity conditions and then testing for their antioxidant activity, total phenol concentrations and 
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21 days under 
these varied conditions in a make-shift chamber and the organoleptic features of the tablets, capsules and 
capsule powders monitored regularly (table 8). The results obtained for antioxidant activity after 21 days 
arized in table 9.  
   
Generally the high temperature and humidity made the capsules fragile (product 7), change colour 
(product 2), caused them to disintegrate (product 6) and/or induced changes in the colour and odour of the 
tablets (products 1 to 4) and capsule powders (products 6 & 7). In at least one case (i.e. product 1) mould 
the SCP, samples of each product were stored exposed and enclosed in its package for 7 to 
are summ
 
Organoleptic properties Suther g landia-containin
product 
(SCP) 
am
ble 2
c d batch 
Pre-stored s
(from ta
ple 
) 
Sealed bat h Expose
1 Bio-Sutherlandia®  
green colour 
it
faint odour 
p
T
 yellow specks.  A 
like growth 
Sharp distinct odour. 
Pale- with 
d 
h a 
Light-green colour w
dark green- yellow s
damp straw odour. 
fine dark green an
yellow specks w
ith fine 
ecks with a 
ablet 
Straw colour with
slight white mould-
present. 
slightly swollen 
2 Sutherlandia SU1® 
n colour
 
een 
mp s
odour.  Tablet slightly swollen. 
 a darker shade of 
green colour. Sharp distinct 
odour. 
Pale- gree   with 
Pale-brownish gr
sharp distinct da
distinct odour
colour with Brittle tablet with
traw-like brownish 
3 Health Wholefoods 
Connection Sutherlandia®
n c
 
w-like
lle
green. 
ld like.  
y-gree
with faint odour
Pale-gra olour 
Pale-gray-green colo
faint damp-stra
ur with 
 odour. Dark
Tablet slightly swo n. 
er shade of grey 
Damp odour…mou
4 Pinnacle Sutherlandia® 
re
ck
istinct odour 
 
t 
nish green with 
odour. 
Pale-brownish g
colour with spe
d
en 
s and a Pale-brownish green
specks and a distinc
colour with 
odour 
Darker shade of brow
sharp distinct 
5 Promune  
ar
fluff
 with a dis
odour 
 g
 clumpy
straw-like  odour 
Pale yellow body and dark green cap 
, otherwise sticky green 
e coating residue.  
nside the whole capsules 
were whitish-gray and clumpy. ®
White body & d k 
kgreen cap, 
Whitish-gray 
powder
y fine 
tinct 
White body & dar
rubbery texture, 
Whitish-gray
reen cap, 
 powder 
when present
and yellow capsul
The powders i
with a distinct 
6  Pro  
 transp
 f
stro
distinct odour 
rent casing, 
ticky texture,  
an
ith 
damp-straw-like  odour 
sintegrated.  
ed of black gunk.  
Foul pungent odour.  Big Tree Sutherlandia ®
casing,  
Pale green fluffy
powder with a 
Large sized arent Large sized transpa
ibrous 
ng 
with rubbery and s
Light green damp 
fibrous powder w
d clumpy 
a strong 
Capsule casing di
Container consist
7 Bi
Medium sized transparent 
les with fragile 
stinctive odour. g Tree Sutherlandia 350® 
Medium sized 
transparent casing, 
Light green fine-fluffy-
fibrous powder and a 
strong distinct odour.   
casing, with rubbery and sticky 
texture, 
Light green fine-fluffy-fibrous 
powder and a strong distinct 
odour.   
Pale yellow capsu
casing.  Pungent di
Table 8: Organoleptic properties of Sutherlandia containing products after exposure to high environmental temperature (40° C) 
and humidity conditions in makeshift chambe .3.1) r for 21 days (see section 4
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antly affected 
the aesthetic and pharmaceutical quality and, most probably, the chemical stability of the SCP.  
 
icon gel packs 
ducts. On the 
he accelerated 
ting (an important part of pharmaceutical quality control) of herbal products such as SCP quite 
problematic.   
 
he aesthetic quality of the products, whether they also mimic changes in the chemical 
constituents and possible efficacy of the products is not known. For this more sensitive tests as discussed 
It was hypothesized that when solid dosage forms of Sutherlandia frutescens are subjected to storage 
under elevated temperature and humidity conditions their antioxidant activity would decrease. To assess 
y of SCP the 
H absorbance 
ons of SCP was determined, the percent inhibition vs. SCP concentration 
plotted (as shown in appendix C) and fitted with a polynomial equation, the IC50 (i.e. concentration of 
 obtained are 
summarised in table 8 and figure 15.   
 
The IC50 values (table 9) for the control group (stored in original packaging in cupboard) of SCP 
(Sutherlandia containing products) ranged between no value for product 6 (Big Tree Sutherlandia Pro®) to 
0.650 mg/ml for Product 5 (Promune®) and 16.114 mg/ml for product 2 (Sutherlandia SU1®).  According 
growth was also evident after 6 days. Clearly the elevated temperature and humidity signific
The SCP appeared to be particularly affected by the elevated humidity. The inclusion of sil
and use of airtight containers (i.e. SCP1, 2, 4, 6 and 7) are thus well warranted for these pro
other hand the vulnerability to humidity would make the use of elevated humidity in t
stability tes
It must however be noted that although the changes in organoleptic features of the SCP indicate gross 
deterioration in t
below are required.   
 
the effect of elevated temperature and environmental humidity on the antioxidant activit
DPPH and FRAP assays were used. For the DPPH assay the percent inhibition of DPP
produced by various concentrati
SCP causing 50% inhibition of the DPPH absorbance) calculated and the results that were
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 the lower the 
IC50 value, the greater the antioxidant activity. No IC50 value could be obtained for product 6 (Big Tree 
Sutherlandia Pro ) because instead of the purple DPPH solution going transparent, a yellow colour 
 of the DPPH 
C). It thus had 
ntrations and 
5 (Promune®) 
Sutherlandia 
SU1 in this respect. In general the SCP thus varied considerably in their levels of antioxidant activity (see 
50 was 
he IC50 values 
Appendix C). 
the method of data analysis the general trend for the antioxidant activity among 
the SCP stored under controlled conditions was however essentially the same as that reported in figure 5 
and table 3 of section 5.2.2.1.  
to Amarowicz et al. (2004) the more rapidly the decrease in absorbance of DPPH occurs and
®
developed, even at low concentrations of the product. The maximum percent inhibition
absorbance by this product was lower than the 50% inhibition level (see graphs in appendix 
a very high level of antioxidant activity which could not be established at the conce
experimental conditions used in this project. With an IC50 value of 0.650 mg/ml Product 
also had substantial antioxidant activity and was much more potent (ca. 25 fold) than the 
control C in fig 14). It must be noted  that for the antioxidant results given in section 5.2.3 the IC
determined by extrapolation from the percent inhibition versus concentration curve while t
in table 9 were obtained by fitting the data with the most suitable polynomial model (
Despite the difference in 
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Key
40oC & 70% RH 
C:   Control conditions; SCP in original package in cupboard  CI: 90% Confidence Interval 
 
 
l, ambient and 
 28°C & 25 to 
caused an increase in the antioxidant activity of the SCP. For instance, the antioxidant activity of product 
2 (Sutherlandia SU1®) increased from 16.114mg/ml for the control group to 5.415mg/ml after storage in 
ambient conditions. The increased antioxidant abilities were significant for all the SCP, except for product 
5.  Product 5, Promune® is the only freeze dried Sutherlandia plant extract product among the selected 
 Table 9: taining products after exposure to elevated temperature and 
environmental humidity using the DPPH assay 
Antioxidant activity of Sutherlandia-con
 
A:  Ambient conditions; SCP stored exposed in laboratory   E: Elevated climatic chamber conditions; 
IC50: Concentration of aqueous extract of SCP producing 50% inhibition of DPPH 
In figure 15 the antioxidant activities of the SCP under the 3 storage conditions (i.e. contro
elevated temperature and humidity conditions) are shown. Storage under ambient (18°C to
35% RH) as opposed to controlled (stored in original packaging in dark and dry cupboard) conditions 
Antioxidant ty activi
 polynomial 
Goodness 
of fit Storage Product Condition Number and Name  IC50 (mg/ml) 
CI  
upper 
limit 
CI 
 lower 
limit 
r2 Order 
C 7.035 7. 6.348 0.951 798 
A 4.196 3.749 0.935  4.694 1.  Bio-Sutherlandia
®  
E No valu N 0.686 
2nd   
e NA A 
C 16.11 no 12.936 0.766 4  value 
A 5.415 7 3.  0.821 .185 8672 Sutherlandia SU  
1® 
E 5.875 no 3.737 0.821 
3  rd
  value 
C 5.246 5 4.954 0.986 .569 
A 3.756 4 2.  0.793 .742 988
3 Health Wholefoods 
Connection Sutherlandia® 
E 7.471 1 5.682 0.739 
2nd 
 1.367 
C 3.794 4 3.405 0.956 .270 
A 2.359 3 1.  0.746 .091 7894 Pinnacle Sutherlandia
® 
E 4.955 no 3.319 0.556 
2nd    
 value 
C 0.650 0. 0.  0.952 773 535
A 0.512 0. 0.466 0.989 565 5 une     
E 0.255 0.224 0.949 
 Prom ® 3rd 
0.295 
C No valu 0.942 e NA NA 
A No valu NA 0.016 e NA 6 Big Tree Sutherlandia Pro®. 
No v 0.376 
2nd 
E alue NA NA 
C 06 3.171 2.7 2.322 0.937 
A 1.277 1.756 0.941 0.700 7  Big Tree Sutherlandia 350® 
E 1.773 2.121 1.517 
2nd 
0.891 
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mbient) was 
statistically insignificant (p=0.075). This could mean that freeze dried extracts are less affected by ambient 
storage conditions. In conclusion, when stored unprotected under ambient conditions the SCP, except the 
us extract (Promune®), changed in organoleptic features (i.e. 
visibly) and exhibited greater antioxidant activity. 
 
SCP and the change in its IC50 values form 0.650mg/ml (control) to 0.512mg/ml (a
capsule containing the freeze dried aqueo
0.000
5.000
10.000
15.000
20.000 Control
IC
50
 (m
g/
m
l)
Ambient
Elevated
1 2 3 4 5 6 7
Sutherlandia  containing products (1-7) under different 
strorage conditions
 
Figure 15 ing products under different storage 
conditions. IC50 = concentration of aqueous extracts of SCP that inhibits UV absorbance of DPPH at 
560nm; SCP 1 to 7 = 7 solid dose Sutherlandia containing products; ambient (A) =18°C to 28°C and 25 to 
ckaging in dark 
 2, 5 & 7 the 
ds Connection 
control group 
ver not statistically significant (p>0.05). It is possible that this 
inconsistency arose because the SCP stored in the climatic chamber were tested after 2 weeks, which may 
have been insufficient time for some products to have changed, and if left longer, e.g. 2 months, all may 
have changed.   
*
*
*
*
*
*
* *
: Comparative levels of antioxidant activities of Sutherlandia contain
37% RH range,  elevated (E) =40oC & 70% RH and Control (C) = stored in original pa
cupboard. N = 3 and * =significant difference from control (p≤0.05, student t-test)  
 
When the SCP were stored at 40oC and 70% RH the outcomes were more variable. For SCP
antioxidant activity was statistically significantly increased. While SCP 3 (Health Wholefoo
Sutherlandia®) & 4 (Pinnacle Sutherlandia®) decreased in antioxidant activity from their 
samples, these decreases were howe
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ant activity in 
the SCP increased when these preparations were stored (exposed) under elevated temperature and humid 
environmental conditions.  It therefore appears that the monitoring of antioxidant activity could be a 
P over time.  
od to use for the SCP since reliable IC50 values 
could not be produced for all the SCP when this method was used.    
ical quality of 
SCP over time, the data obtained using the ferric reducing antioxidant power (FRAP) assay was also 
assessed. A standard curve of ascorbic acid concentration vs. absorbance at 540nm described by the 
d and used to calculate the ascorbic acid 
antioxidant equivalents of each SCP stored under the different  environmental temperature and humidity 
conditions, see table C.1. The results obtained are summarized in figure 16.  
Overall the data thus suggested, contrary to the postulated hypothesis, the level of antioxid
reliable method to monitor, control and/or compare the pharmaceutical quality of SC
However, the DPPH assay may not be a very viable meth
 
To confirm that monitoring of antioxidant activity can be used to compare the pharmaceut
equation, y = (5.440±0.1698)x + (0.1338±0.009049), was obtaine
0
1 2 3 4 5 6 7
Sutherlandia containin
1
2
3
4
5
6
g products (1-7)under different 
storage conditions
Control 
Ambient
FR
AP
 (m
g/
m
l A
AE
)
Elevated
 
Figure 16: Comparative levels of antioxidant activities (FRAP) of aqueous extracts of Sutherlandia containing 
products under different storage conditions. FRAP = Ferric Reducing antioxidant power; SCP 1 to 7 = 7 
solid dose Sutherlandia containing products; ambient (A) =18°C to 28°C and 25 to 37% RH range,  elevated 
(E) =40oC & 70% RH and Control (C) = stored in original packaging in dark cupboard. N = 3 and * 
=significant difference from control (p≤0.05, student t-test)  
 
*
*
*
*
*
* **
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 convert ferric 
acid to ferrous at lower concentrations and thus, the greater the antioxidant ability. The results for SCP 2 
to 7 all increased in antioxidant activity after 2months of storage under am e increase 
® 6 (Big Tree 
ant activity of 
reased (i.e. from 1.133789 to 1.209806mg/ml AAE) although this decrease was not 
statistically significant. 
The samples stored under elevated temperature and humidity seemed to follow the trend of a decrease in 
® ® idant activity 
nd humidity conditions, however only SCP 7 had a significant 
difference. One can assume that, climatic chamber conditions decreases the ability of each product to 
transform these irons at lower concentrations.   
From figure 16, product 5 (Promune ) appeared to be the least affected when exposed to extreme (40°C 
bient, and 
control and elevated temperature and humidity stored samples were 0.775 and 0.251mg/ml AAE 
tions had no 
Thus, climatic chamber storage (elevated group) decreased the antioxidant activity of most of the SCP, 
whereas the ambient stressed samples either had little effect, or actually increased the antioxidant ability 
of the SCP samples. As in nature, according to Ksouri et al. (2008), secondary metabolites, such as 
phenols which contribute to antioxidant activity, are 1.4 fold higher in medicinal plants growing in arid 
environments compared to those found in humid environments. Research conducted by Stafford et al. 
The lower the ascorbic acid equivalence (AAE) result of the SCP, the greater their ability to
bient conditions. Th
was however only statistically significant (p≤0.05) for SCP 2 (Sutherlandia SU1 ), 
Sutherlandia Pro®) and SCP 7 (Big Tree Sutherlandia 350®). On the other hand, the antioxid
SCP 1 actually dec
 
antioxidant activity, SCP 1, 3, 4 and 6 had statistically significant (p≤0.05) decreased in antioxidant levels.  
The SCP 5 (Promune ) and 7 (Big Tree Sutherlandia 350 ) seemed to increase in antiox
after storage in elevated temperature a
  
®
and 70%RH) storage conditions, the antioxidant ability p values between the control and am
respectively. Thus the difference in antioxidant ability between these storage condi
statistically significant effect on SCP 5 when using the FRAP assay. 
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synthesis, was 
either stable or increased during storage of dried medicinal plants under ambient conditions, whereas 
accelerated aging (55ºC and 100% RH) decreased the anti-inflammatory effects of certain medicinal 
contributed to 
ake up of the 
idant activity 
 in warm and 
ay be used to 
monitor, control and compare pharmaceutical quality of SCP over time, provided that storage humidity 
idity 
e total phenol content (TPC) of the Sutherlandia containing products, the Folin-
Ciocalteu assay was conducted on all samples. The TPC results obtained are recorded in Appendix D and 
summarized in figure 17. 
(2005) concluded that anti-bacterial activity, which is also a result of secondary metabolite 
plants.  Stafford et al. (2005) also stated that changes in biological material cannot be 
storage conditions alone, but also upon the drying process, which could affect the chemical m
plant material. These arguments together with the results of this study suggests that antiox
will either increase when in warm and dry storage conditions or decrease when stored
moist/humid storage conditions. Thus antioxidant activity assays, mainly the FRAP assay, m
conditions are noted. 
 
To test and compare the effect that storage under ambient and elevated temperatures and hum
conditions had on th
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l c
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: Comparative levels of total phenol levels of aqueous extracts of Sutherlandia containing
different storage conditions. GAE = gallic acid equivalence, SCP1 to 7 = 7 solid do
containing produc
Figure 17  products under 
se Sutherlandia 
ts; ambient (A) =18°C to 28°C and 25 to 37% RH range, Elevated (E) =40oC & 70% 
RH and Control (C) = stored in original packaging in dark cupboard. N = 3 and * =significant difference 
from control (p≤0.05)  
 
In general, storage under ambient conditions (i.e.18°C to 30°C and 10 to 30% RH range) caused an 
increase in the total phenol content of the SCP constant with that of the “control“ samples (i.e. sample 
icant (P<0.05) 
ol levels of all 
and 6 decreased significantly (p<0.05) compared to that of the samples stored under control conditions.  
This implies that under these conditions the phenols in the SCP are overwhelmingly degraded, evidently, 
just 2 weeks storage in a climatic chamber under 40°C and 70% RH was sufficient to produce degradation 
of not only the existing free phenols but also those that may initially have formed from  phenol conjugates.  
*
*
*
*
*
**
**
stored in original package in cupboard). All the products except, SCP 2 and 7 had signif
increases in their TPC when stored under ambient conditions.  
 
Upon storage under climatic chamber stress conditions (i.e. 40°C & 70% RH) the total phen
the SCP decreased compared to the levels of the control group. The ambient stored samples of SCP 2, 4, 5 
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age conditions 
show that high relative humidity decreases total phenol content and increase in temperature alone 
increases total phenol content. This result was contrary to the set hypothesis that the total flavonoid and 
polyphenol levels may decrease or remain unchanged. 
 of plants are 
e dried plant 
antioxidant activity, thus at higher concentrations of SCP it is anticipated that the TPC and antioxidant 
and biological 
cess will also 
e under ambient conditions could have 
removed some of the moisture of the “dried” plant material of the solid dosage forms of the SCP, thus 
concentrating the TPC and elevating the antioxidant ability of that product. 
 
ored under the different 
environmental storage conditions were similar to that of the antioxidant results. This strongly suggests that 
ality, stability 
s.  
Some of the most important phenols with antioxidant activity in the SCP may be the flavonoids. To test 
and compare the effect that storage under ambient and elevated temperatures and environmental relative 
humidity conditions had on the flavonoid profile of SCP HPLC analysis was conducted. The peaks that 
were most prominent in all the 7 SCP were identified as Sutherlandins A to D as previously recorded by 
Avula et al. (2010), were used to quantitate the effect of the different storage conditions on the SCP. 
The results of both the ambient and elevated environmental temperature and humidity stor
  
According to Ksouri et al. (2008) and Kirakosyan et al. (2003), the secondary metabolites
enhanced when subjected to elevated and dry environments. This proves true for th
material/products too (Stafford et al., 2005). These secondary metabolites, (i.e. phenols) contribute to 
activity will increase when subjected to high temperatures and low humidity for a long period.  However 
as stated by Stafford et al. (2005) storage conditions alone do not contribute to the chemical 
properties of the medicinal plant, the manner in which the product is prepared, i.e. drying pro
effect these total phenol and antioxidant levels. Thus storag
In general the trends in the change in total phenol content among the 7 SCP st
the use of total phenol content monitoring may be a useful tool to assess the long term qu
and shelf life of commercially available Sutherlandia containing pharmaceutical dosage form
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The sutherlandins had retention times of 10.928, 11.969, 14.373 and 15.040mins, respectively and these 
were used to analyse the HPLC fingerprints of SCP that had been subjected to storage under ambient (18 
se fingerprints 
erlandins A to 
s of the SCP stored under the different environmental conditions are summarized 
in figures 17 to 20 below.   
 
to 30°C) and 40°C and 70 % RH (i.e. Elevated climatic chamber storage). Samples of the
are given in Appendix G and H and the changes in the height of the 4 relevant peaks (suth
D) in the chromatogram
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Figure 18:  The effect of different environmental storage conditions on the height of the 
Sutherlandin A peak (retention time =10.928min) obtained for 7 SCP. 
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Figure 19:  The effect of different environmental storage conditions on the height of the 
Sutherlandin B peak (retention time =11.969min) obtained for 7 SCP. 
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Figure 20:  The effect of different environmental storage conditions on the height of the 
Sutherlandin C peak (retention time = 14.373min) obtained for 7 SCP. 
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eights of sutherlandins A to D increased or decreased after 
the SCP were stored under different environmental conditions (i.e. Control, Ambient and Elevated). All 
environmental 
conditions, all except product 6 (  Pro ).     
 
When conducting statistical student t-test on all the SCP stored under different environmental conditions, 
sutherlandin A had  the most significant increase in peak heights between the control and ambient stored 
group, where p=0.0136, and the control and elevated conditions stored group p=0.0072. The peak heights 
Figure 21:  The effect of different environmental storage conditions on the height of the 
Sutherlandin D peak (retention time =15.040min) obtained for 7 SCP. 
 
 
Figures 18 to 21 simplifies whether the peak h
SCP samples had increased sutherlandin peak heights after storage in elevated and ambient 
Sutherlandia ®
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 ambient, and 
the control and elevated stored samples, however sutherlandin D had the least significant (p=0.0418) 
change between the control and ambient stored samples. 
PC decreased 
ins increasing 
d suggest that 
exact values of the heights see table I.1 in the appendices. These results are contrary to the earlier 
hypothesis which states that levels of flavonoid glycosides will decrease after exposure to elevated 
s actually had 
ity conditions, 
providing compelling evidence that high humidity decreases the amount of secondary metabolites being 
expressed by the SCP (Stafford et al., 2005). As a further study it would be best to have HPLC chromatic 
d compare them to 
two month ambient exposure. 
roducts  
Solid dose Sutherlandia products contain constituents such as flavonoid glycosides that may vary in their 
susceptibility to acid hydrolysis and in their release of active compounds in acidic environment (e.g. 
stomach) which in turn may lead to variable absorption, bioavailability and consequently, variable in-vivo 
effects from the dosage form. Variability in susceptibility to acid hydrolysis can thus be used to ascertain 
inconsistency in quality among SCP.  
of sutherlandins B, C and D also increased significantly (p≤0.05), between the control and
 
These results are conflicting with those of the total phenol content assay test, where the T
when exposed to elevated temperature and humidity. However the individual sutherland
when stored in ambient conditions, this increase correlates with the TPC results. This coul
the sutherlandins are not the only phenols which contribute to the total phenol content of the SCP. For the 
environmental temperature and humidity conditions. 
 
Another interesting find from these results during ambient storage conditions, sutherlandin
greater concentrations than when stored in elevated environmental temperature and humid
fingerprints of SCP which have been exposed to a climatic chamber for two months an
 
5.2.6 The effect of acid hydrolysis on solid dose Sutherlandia frutescens containing p
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To determine the effect of acid hydrolysis on the quality of the SCP the products were exposed to 0.6N 
hydrochloric acid solution for up to 24hours and then analyzed using HPLC. The chromatographic 
tained for the hydrolyzed and unhydrolysed (control) solutions of SCP groups are given in 
figures 21 to 27.   
fingerprints ob
 
Figure 22: Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red line) solution of 
After acid hydrolysis of SCP1, the chromatographic peaks eluting in the first 10minutes of the HPLC run 
(figure 22) were essentially the same as those for the unhydrolysed sample. However, the flavonoid 
(& previously 
) for the un-hydrolysed sample disappeared completely 
from the chromatographic fingerprint of the acid-hydrolyzed sample while the peaks at the retention time 
of 13.771±0.055 and 17.909±0.05mins with flavonoid-like spectrum appeared to be slightly higher (9.4 to 
20.8 and 5.4 to 33.7mAU’s respectively) after hydrolysis.   
 
Sutherlandia containing product 1. 
 
compounds eluting at the retention times of 10.802, 11.908, 14.274, and 14.956mins 
identified as sutherlandin A to D, see section 5.2.4
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Figure 23: Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red line) solution of Sutherlandia 
containing product 2. (Note that the scale for the red and blue traces are not the same; height of peak at 17.935min in 
red and blue traces are <0.01mAU’s, and 1.7mAUs, respectively) 
 
 in the SCP 2 
 of 13.84 and 
 blue traces in 
un-hydrolysed 
SCP 3, 4, 6 and 7 (figures 24 to 27), except that the peak at 17.805±0.15mins did not change much in peak 
height. It is suspected, from the presently available MS data, that the compound at 17805±0.15mins is a 
breakdown product of sutherlandin C and D i.e. a kaempferol derivative.   
 
      y         z x       
After acid hydrolysis, the 4 sutherlandin peaks at 10.875, 11.915, 14.295 and 14.965mins
fingerprint (figure 23) also disappeared while the height of the peaks at retention times
17.935mins (also seen in SCP 1) was reduced.  It must be noted that the scale for the red and
figure 23 is not the same i.e. the heights for the 17.935mins peaks in the hydrolysed and 
samples were <0.01, and 1.7mAUs, respectively. Similar results were obtained after the acid hydrolysis of 
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Figure 24:  solution of 
Sutherlandia containing product 3. (Note that the scales for the red and blue traces are not the same; 
heights of peak at 17.886±0.034min in red and blue traces are 7.9, and 6.4 mAUs, respectively) 
 
 
Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red line) 
 
Figure 25: Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red line) solution of 
Sutherlandia containing product 4. (Note that the scales for the red and blue traces are not the same; 
heights of peak at 17.899±0.016min in red and blue traces are 6.9, and 9.4 mAUs, respectively) 
 
 
 
 
 
 
 
 
Figure 26: Chromatographic fingerprint of hydrolysed Sutherlandia containing product 6. (Note that the scales for the 
red and blue traces are not the same; height of peak at 17.894min in red and 16.790min in the blue traces 
are 3.2, and 3.3mAUs, respectively) 
 
 
 
ne) solution of 
Sutherlandia containing product 7. (Note that the scales for the red and blue traces are not the same; 
heights of peak at 17.921±0.005min in red and blue traces are 6.8, and 7.6mAUs, respectively) 
 
It thus appears that acid hydrolysis causes the degradation of at least 4 flavonoid-like compounds 
(sutherlandins) in the SCP 1 to 4 and 6 & 7. From the present results it is however not clear what break 
Figure 27: Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red li
 67
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ry likely, from 
the present data, that such aglycones were also susceptible to acid-hydrolysis. 
down products resulted from this degradation.  If they are converted to the aglycones it is ve
 
ne) solution of 
Sutherlandia containing product 5. 
Product 5 also 
11.53±0.25, 13.74±0.36, and 14.41±0.48mins. These flavonoids also disappeared or were reduced after 
acid hydrolysis (figure 28). For product 5, as was the case for the other SCP, the peak at 17.13±0.54mins 
he results for 
onoid-like peak at 13.725mins 
which was much more prominent in the Promune® than the other products also decreased (from 321.3 to 
he compound 
 
Under the same HPLC conditions the aglycone quercetin had retention times of 10.271±0.02min (n= 3).  
The chromatograms for the SCP after acid hydrolysis contained no peaks at this retention time suggesting 
that even aglycones was susceptible to acid hydrolysis.  
Figure 28:  Chromatographic fingerprints of unhydrolysed (blue line) and hydrolysed (red li
 
As reported earlier (section 5.2.4) the fingerprint of the un-hydrolysed aqueous solution of 
had, as seen in the other products, the 4 prominent sutherlandin peaks at retention times 10.51±0.21, 
was also present and decreased in height from 268.5 to 36.8mAU’s after acid hydrolysis. T
product 5 also differed slightly from that for the other SCP in that it the flav
49.2mAU) after acid hydrolysis. It is suspected, from the presently available MS data, that t
at 13.7mins is a breakdown product of sutherlandin A and B i.e. a quercetin derivative.    
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were significantly degraded under acidic conditions. The flavonoids-like peaks at the retention times 
ctively. These 
erlandins (i.e. 
resence of the 
ble to the acid 
hydrolysis (Nuutila et al., 2002). The hypothesis that the levels of free aglycone flavonoids will decrease 
after environmental elevation was accepted. These results mean that the sutherlandins contained in the 
ailability after 
ore thorough investigation of the acid induced hydrolysis of the sutherlandins in 
the SCP (i.e. determination of the actual rates of breakdown, the identity and stability of the breakdown 
 
5.2.7 Quality control specifications that may be used for the selected Sutherlandia frutescens 
omparing the 
nd robust, and 
aring product 
quality antioxidant activity and TPC are excellent markers, however longer periods of environmental 
stress should be conducted on these products. Promune® or rather aqueous freeze dried extracts of S. 
frutescens could be used to isolate large amounts of sutherlandins A to D, which can be used as standards 
in HPLC analysis to quantify the levels of each flavonoid (sutherlandin) in each SCP. Of the methods used 
Overall, it was clear that the 4 sutherlandins (section 5.2.4) identified in the SCP investigated in this study 
around 13.69±0.114, and 17.805±0.153mins, were most likely those of derivatives of quercetin and 
kaemferol, respectively, and break down products of sutherlandins A & B and C & D, respe
were also susceptible to acid hydrolysis but not to the same extent. It is likely that the suth
flavonoid glycosides) are hydrolysed to their aglycone forms but since no evidence of the p
latter was obtained in the present study it is likely that even the aglycones were also suscepti
SCP may not be very stable in acidic pH (as in the stomach) and this may affect their bioav
oral administration. A m
products, etc.) is warranted.  
preparations  
 
Based on the results of the set objectives, antioxidant activity is an effective means of c
different SCP quality and could be used in industry as a golden standard. It is inexpensive a
when performed on micro-plates many replicates can be run simultaneously. For comp
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ns) and HPLC 
analysis, are excellent means of testing solid dose Sutherlandia frutescens containing product quality.  
  
vailable solid 
d to elevated 
 analysing the 
 environmetal 
 
feasible to establish which sutherlandin contributes to the most antioxidant ability of Sutherlandia 
frutescens, this would shorten the quality assessment of each solid dose SCP by only using HPLC analysis 
to quantify that specific sutherlandin.   
to test product quality and comparison, the DPPH assay (taken into far lower concentratio
Antioxidant activity and flavonoid levels can be used to assess the quality of commercially a
Sutherlandia frutescens products, however both these properties decrease when expose
environmental humidity conditions. The only possible way to compare SCP optimally is by
contents of each product on the date of manufacture and then storing it under elevated
temperature and humidity to establish an appropriate expiration date. As a further study it would be 
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CONCLUSION AND RECOMMENDATION 
nd antioxidant 
e 
Sutherlandia frutescens containing products (viz. tablets & capsules) and to develop/or adapt methods and 
ed for the quality control of such products.  
The objectives of this study were: 
 solid dose S. 
ucts,   
 To determine and compare the antioxidant activity of selected commercially available solid dose S. 
frutescens containing products, 
containing 
s, 
 ine the effect of various environmental stresses [i.e.  elevated temperature, environmental 
humidity and chemically-induced (or acid-induced) degradation] on the selected products, and 
  To formulate quality control specifications that may be used for the selected Sutherlandia frutescens 
preparations. 
 
 
Chapter 6
 
 
The overall aims of this project were to explore the use of monitoring flavonoid profile a
activity levels to assess the pharmaceutical quality and consistency of commercially available solid dos
specifications that may be us
 
 To assess and describe the quality and regulatory compliance of selected representative
frutescens containing prod

 To compare the total phenol level of selected representative solid dose S. frutescens 
products,   
  To determine the profile and level of specific flavonoids in the above mentioned product
 To determ
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6.1 Conclusion and Recommendations 
 
Based on the results obtained the following conclusions could be drawn: 
1. dy, physically 
n the date of 
 insufficient 
information. It should be feasible that present commercially available solid dosage Sutherlandia-
2. st antioxidant 
landia Health 
 > Big Tree Pro® >>Phyto Nova SU1®. The capsules 
possessed greater antioxidant power than the tablets and the two assays (FRAP and DPPH) were useful 
in comparing the relative potencies of the selected SCP. 
3. ® Tree 350® >> 
 Big Tree Pro® > Phyto Nova SU1® > Sutherlandia Health Connection 
r the selected 
 potencies and 
4. All the selected SCP contained the flavonoids sutherlandins A to D in varying amounts with the 
sutherlandin C being the most concentrated in all the SCP and the capsules having far greater levels of 
all these flavonoids than the tablet dosage form. These flavonoids can thus be used as marker 
compounds and be quantified to compare and monitor the relative pharmaceutical quality (e.g. content 
uniformity, expiry date, etc) of Sutherlandia containing solid dose products 
 
 The Sutherlandia-containing tablet and capsule dosage forms investigated in this stu
appeared to be of quite good “pharmaceutical” quality, but generally lacked information o
manufacture and lacked package inserts, or when these were present they contained
containing products could, with relatively little extra information, easily meet most of the product 
quality criteria needed for their registration by the MCC.     
 All the SCP had antioxidant activity which ranged, in descending order of greatest to lowe
power, as follows: Promune® >> Big Tree 350® >> Sutherlandia Pinnacle® > Suther
Connection Wholefoods® > Bio-Sutherlandia®
The SCP varied in total phenol concentration in descending order: Promune  >> Big 
Sutherlandia Pinnacle® >
Wholefoods® > Bio-Sutherlandia®, which correlated with the antioxidant activity results fo
SCP. Both the antioxidant activity and TPC results gave good indications of the relative
chemical integrity of the SCP.  
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uality and the 
chemical stability of the SCP. The SCP appeared to be particularly affected by the elevated humidity 
which caused a decrease in the total phenol content of the products. Careful consideration of the storage 
ant containers 
ging, inclusion of silica sachets, etc.) is thus required if the long term stability of SCP is to be 
6. herlandins are 
eptible to 
acid hydrolysis but not to the same extent.  In this process aglycones are either not formed or very rapidly 
ach) 
ore thorough investigation of the 
acid induced hydrolysis of the sutherlandins in the SCP (i.e. determination of the actual rates of 
e breakdown products, etc.) is warranted.  
 
Based on the results obtained it is recommended that, 
1) the manufacturers of SCP pay more attention to the information provided on the package inserts and the 
  
2) the levels of antioxidant activity, total phenols and flavonoids (sutherlandins A to D) be used as 
specifications to control the quality of commercially available solid dose Sutherlandia frutescens 
containing preparations on an individual basis. 
 
 
 
 
 
5. Elevated temperature and humidity significantly affected the aesthetic, pharmaceutical q
conditions, particularly those that reduce the effects of humidity (e.g. use of moisture-resist
or packa
ensured.   
 The SCP were very susceptible to acid hydrolysis. Under these conditions the 4 sut
ssignificantly degraded to derivatives of quercetin and kaempferol, which in turn are also susc
degraded. The sutherlandins contained in the SCP are thus not very stable in acidic pH (as in the stom
and this may affect their bioavailability after oral administration. A m
breakdown, the identity and stability of th
storage conditions for their products and
 
 
 
 
 74
S 
 
1)  
y suppressed 
tection and cryptand column.  Journal of Pharmaceutical and Biomedical 
Analysis 48:467-471 
2) . Free-radical 
scavenging capacity and antioxidant activity of selected plant species from the Canadian pairies.  
 
3) Atawodi, S. (2005).  Antioxidant potential of African medicinal plants.  African Journal of 
 
4)  W., Syce, J., 
han, I.K.  (2010). Quantitative determination of flavonoids and 
cycloartanol glycosides from leaves and stems of Sutherlandia frutescens (L.) R.  BR. by using 
aceutical and 
 
5) Bandaranayake, W.M.  (2006)  Quality Control, Screening, Toxicity, and Regulation of Herbal 
  WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim.   ISBN: 3-527-31530-6 
6) a Measure of 
tical Biochemistry 239: 70–76  
 
 cing 
power-based antioxidant capacity assays in the presence of phenanthroline, tripyridyltriazine 
(FRAP), and ferricyanide reagents.  Talana 72:1157-1165 
 
8) Brand-Williams, W., Cuvelier, M.E., Berset, C.  (1995). Use of a Free Radical Method to 
Evaluate Antioxidant Activity.  Lebensm.-Wiss. U.-Technol. 28:25-30 
 
REFERENCE
Abballe, F., Lombardi, M., Maccone, I., Palazzo, G. Severoni, A., Travaini, S., Venturini, A. 
(2008). New method for low molecular weight heparin quantification in tablets b
conductivity de
 
Amarowicz, R., Pegg, R.B., Rahimi-Moghaddam, P., Barl, B., Weil, J.A.  (2004)
Food Chemistry 84:551-564   
Biotechnology 4, 2:128-133 
Avula, B., Joshi, V.C., Wang, Y-H., Smillie, T.J., Fu, X., Li, X.C., Mabusela,
Johnson, Q., Folk, W., K
LC-UV/ELSD methods and confirmation by LC-MS method. Journal of Pharm
Biomedical Analysis 52: 173-180  
Drugs.  Modern Phytomedicine. Turning Medicinal Plants into Drugs.
 
Benzie, I., Strain, J. (1996).  The Ferric Reducing Ability of Plasma (FRAP) as 
‘‘Antioxidant Power’’: The FRAP Assay.  Analy
7) Berker, K. I., Güçlü, K., Tor, İ., Apak, R.  (2007). Comparative evaluation of Fe (III) redu
 
 
 
 
 75
 s in cultured 
: 163–170 
 
10) . Flavonoid content of several vegetables and their 
antioxidant activity.  J. Sci. Food Agric. 80: 561-566  
11) ical methods for assessing total 
antioxidant capacity of human serum.  Clinical Chemistry 44, 6: 1309–1315 
 
12) orin, P. A.J., 
vonol glycoside isomers from leaves of Maytenus ilicifolia 
by offline and online high performance liquid chromatography–electrospray mass spectrometry. 
 
13) pound of garlic, induces 
 generation of reactive oxygen 
species and activation of nuclear factor ΚB.  Molecular Pharmacology, 53:402-407 
14) A).  (2006) London ©EMEA 
 
) flavonoids by 
HPLC and effect of aging.  Food Chemistry 101:428-433 
16)  and Chronic Inflammation. Frontiers in 
Bioscience 2: 12-26 
17) idant potential 
 95: 1–5 
 
18) Fu, X., Li, X-C., Wang, Y-H., Avula, B., Smillie, TJ., Mabusela, W., Syce, J., Johnson, Q., Folk, 
B., Khan, IK.  (2010). Flavonol glycosides from the South African medicinal plant Sutherlandia 
frutescens. Planta Medica 76: 178-181 
 
19) Fu, X., Li, X-C., Wang, Y-H., Smilie, TJ.,Carvalho, P., Mabusela, W., Syce, J., Johnson, Q., 
9) Chinkwo, K.A. (2005). Sutherlandia frutescens extracts can induce apoptosi
carcinoma cells. Journal of Ethnopharmacology 98
Chu, Y-H., Chang, C-L., Hsu, H-F.  (2000)
 
Cao, G., Prior, R.L.  (1998). Comparison of different analyt
De Souza, L.M., Cipriani, T.R., Serrato, R.V., da Costa, D.E., Iacomini, M., G
Sassaki, G. L.  (2008). Analysis of fla
Journal of Chromatography A 1207: 101–109 
Dirsch, V.M., Gerbes, A.L., Vollmar, A.M.  (1998).  Ajoene, a com
apoptosis in human promyeloleukemic cells, accompanied by
 
European Medicines Agency Inspections (EME
15 Fang, F., Li, J-M., Pan, Q-H., Huang, W-D.  (2007). Determination of red wine 
 
Feghali, C.A., Wright, T.M. (1997).  Cytokines in Acute
 
Fernandes, A., Cromarty, A., Albrecht, C., van Rensburg, C. (2004).  The antiox
of Sutherlandia frutescens. Journal of Ethnopharmacology
 
 
 
 
 76
ia frutescens.  
20) frutescens’, Terra 
wed on May,19 2008, <http://www.africanherbs.info/docs/Intro_Sutherlandia-
kankerbossie.pdf>  
 
21) Mayeng, B., Mutwa, C., Hutchings, A. (2001). 
 
22) squale, R., Catania, S.  (2006). 
Evaluation of the antioxidant properties and bioavailabilities of free and bound phenolic acids 
 
23) ma 
total antioxidant ability on lipid and protein oxidation products in plasma and erythrocyte ghost 
ns.  Molecular 
stry 267: 195-201 
 
) lant analysis. 
 
) idant activity, 
nal of Agricultural and Food 
chemistry 53: 6117-6125  
26) trial Potential of 
Temperate Legumes. Australia: CRC Salinity Bulletin 2/2006 ISSN 1833-4237 
 
27) Johnson, Q., Syce, J., Nell, H., Rudeen, K., Folk, W. R. (2007).  A Randomized, Double-Blind, 
Placebo-Controlled Trial of Lessertia frutescens in Healthy Adults. Plos Clinical Trials 16: 1-7 
 
28) Katerere, D. Eloff, J.  (2005). Antibacterial and antioxidant activity of Sutherlandia frutescens 
(Fabaceae), a reputed anti-IV/AIDS phytomedicine.  Phytotherapy Research 19: 779-789 
Folk, W., Avery, A., Khan, IA. (2008). Cycloartane glycosides from Sutherland
Journal of Natural Products 71: 1749-1753 
 
Gericke, N., Albrecht, C., van Wyk,B., Mayeng, B. ‘Introduction Sutherlandia 
Treatment. Vie
Gericke, N., Albrecht, C.F., Van Wyk, B.-E., 
Sutherlandia frutescens, Aust. J. Med. Herb. 13: 9–15. 
Gemanỏ, M., D'Angelo, V., Biasini, T., Sanogo, R., De Pa
from Trichilia emetica Vahl.  Journal of Ethnopharmacology 105: 368-373 
Hadi, A.H., Abdolamir, A., Mahtab, H., Abolfazl, D., Yusef, R.  (2004). Influence of plas
obtained from developing and adult rats pre-treated with two vitamin K formulatio
and Cellular Biochemi
24 Harborne, J.B. (1973) Phytochemical Methods.  A guide to Modern techniques of p
London: Chapman and Hall 
25 Hsu,H., Houng, J., Chang, C., Wu, C., Chang, F., Wu, Y. (2005).  Antiox
cytotoxicity, and DNA Information of Glossogyne tenuifolia. Jour
 
Humphries, JM., Hughes, SJ. (2006). Pharmaceutical, Nutraceutical and Indus
 
 
 
 
 77
 
 
 of oxidant-mediated inflammatory disorders.  
Complementary Therapies in Medicine 15: 207-216 
30) S.C.  (2003). 
nd Crataegus 
rn) subject to drought and cold stress. Journal of Agricultural and Food 
 
31) Kondo, K., Kurihara, M., Miyata, N., Suzuki, T., Toyoda, M.  (1999). Mechanistic studies of 
-86 
 
32) Kroll, U., Cordes, C.  (2006). Pharmaceutical prerequisites for a multi-target therapy.  
 
33) Ksouri, R., Megdiche, W., Falleh, H., Trablsi, N., Boulaaba, M.,  Smaoui, A., Abdelly, C.  
c content and 
73 
 
34) Lai, J., Lim, Y., Su, J., Shen, H., Ong, C. (2007).  Identification and characterization of major 
Journal 
of Chromatography B 848: 215-225 
35) itrus peels I. Solvent 
extraction method.  Separation and Purification Technology 48: 182-188 
36) 
8-497 
 
37) Lieberman, H.A., Reiger, M.M., Banker, G.S.  (1998). Pharmaceutical dosage forms: Disperse 
29) Kaplan, M., Mutlu, E.A., Benson, M., Fields, J.Z., Banan, A., Keshavarzian, A. (2006). Use of 
herbal preparations in the treatment
 
Kirakosyan, A., Seymour, E., Kaufman, P.B., Warber, S., Bolling, S., Chang, 
Antioxidant capacity of phenolic extracts from the leaves of Crataegus laevigata a
monogyna (Hawtho
Chemistry 51: 3973-3976 
catechins as antioxidants against radical oxidation.  Arch. Biochem. Biophys. 362: 79
Phytomedicine 13: 12–19 
(2008). Influence of biological, environmental and technical factors on phenoli
antioxidant activities on Tunisian halophytes.  Coptes Rendus Biologies 331: 865-8
flavonoids and caffeoylquinic acids in three Compistae plants by LC/DAD-APCI/MS.  
 
Li, B., Smith, B., Hossain, M.  (2006). Extraction of phenolics from c
 
Li, X.I., Li, X.L., Zhou, A. (2007).  Evaluation of antioxidant activity of the polysaccharides 
extracted from Lycium barbarum fruits in vitro. European Polymer Journal 43: 48
Systems. Volume 3. Second edition.  Marcel Dekker Inc.  United States of America.    
 
38) Mander, M. Marketing of indigenous medicinal plants in South Africa-A case study in Kwazulu-
 
 
 
 
 78
28, 2008, < 
39) . (2003).  Photographic guide to the wildflowers of South Africa
Natal. FAO, Food Corporate Document Repository. (1998) viewed on June 
http://www.fao.org/docrep/w9195e/w9195e00.HTM>. 
 
Manning, J . Briza Publications.  
South Africa.  
40) d EMEA guidlines on drug 
development in relation to Phase 0 trails.  British Journal of Cancer 97: 577-581  
 
41) arova, F., Atanassova, M. (2005).  Total Phenolics and Total FlavonoidsIn 
Bulgarian Fruits and Vegetables. Journal of the University of Chemical Technology and 
 
42) Merken, M.H., Beecher, G.R. (2000).  Liquid chromatographic method for the separation and 
: 177-184 
 
43) Mills, E., Cooper, C., Seely, D., Kanfer, I. (2005).  African herbal medicines in the treatment of 
rition Journal 
 
) l (DPPH) for 
Songklanakarin Journal Science Technology 26: 211-219 
 
) n of methods 
h for HPLC analysis. 
Food Chemistry 76: 519–525 
46)  R. BR (variety 
Incana E. MEY.)[Fabaceae] shoot aqueous extract.  Brain Research Bulletin 75: 126-132 
 
47) Prevoo, D., Smith, C., Swart, P., Swart, A.C.  (2001). The effect of Sutherlandiafrutescens on 
steroidogenesis: confirming indigenous wisdom.  Endocr. Res. 30: 745–751 
 
 
Marchetti, S., Schellens, J.H.M.  (2007).  The impact of FDA an
Marinova, D., Rib
Metallurgy 40: 255-260 
quantification of prominent flavonoid aglycones.  Journal of Chromatography A 897
HIV: Hypoxis and Sutherlandia.  An overview of evidence and pharmacology.  Nut
4: 19  
44 Molyneux, P.  (2004). The use of the stable free radical diphenlpicrylhydrazy
estimating antioxidant activity.  
45 Nuutila, A.M., Kammiovirta, K., Oksman-Caldentey, K.-M.  (2002).  Compasiso
for the hydrolysis of flavonoids and phenolic acids from onion and spinac
 
Ojewole, J.A.O.  (2008). Anticonvulsant property of Sutherlandia frutescens
 
 
 
 
 79
) lfway House, 
 
49) lutions for static control of relative humidity between 5° 
and 40° C.  Analytical Chemistry 32: 1375-1376 
 
50) Rood, B.  (1994). Uit die Veldapteek. Tafelberg Publishers, Cape Town, South Africa. 
51) Roura, E., Andrẻs-Lacueva, C., Estruch, R., Lamuela-Raventỏs, R. (2006).  Total Polyphenol 
 52: 749-752 
 
52) er, R., Lamuela-Raventỏs, R. (1999).   Analysis of total phenols and other 
oxidation substrates and antioxidants by means of Folin-Ciocalteu Reagent. Methods in 
 
53) Stafford, G.I., Jäger, A.K., van Staden, J. (2005). Effect of storage on the chemical composition 
. Journal of 
 
)  Sutherlandia 
 
)  on the DPPH 
cy. A kinetic approach for the 3', 4'-hydroxy substituted 
members. Innovative Food Science and Emerging Technologies 7: 140-146 
56) orn, B., Gericke, N. (1997).  Medicinal Plants of South Africa. 
Briza Publications, Pretoria, South Africa 
 
57) Verma, I.M. (2004).  Nuclear factor (NF)-κB proteins: therapeutic targets. Annals of the 
Rheumatic Diseases 63: 1157-1161  
 
58) Vijaykumar, S., Pesannakumar, G., Viayalakshmi, N.R. (2008).  Antioxidant activity of banana 
flavonoids.  Fitoterapia 79: 279-282   
48 Roberts, M. (1990). Indigenous Healing Plants. Southern Book Publishers, Ha
South Africa. 
Rockland, L.B.  (1960). Saturated salt so
 
intake estimated by a Modified Folin-Ciocalteu Assay of urine.  Clinical Chemistry
Singleton, V., Orthof
Enzymology 299: 152-178 
and biological activity of several popular South African medicinal plants
Ethnopharmacology 97: 107-115 
54 Tai, J., Cheung, S., Chan, E., Hasman, D.  (2004). In vitro culture studies of
frutescens on human tumor cell lines.  Journal of Ethnopharmacology 93: 9-19 
55 Tsmongiannis, D., Oreopoulou, V. (2006).  The contribution of flavonoid C-ring
free radical scavenging efficien
 
Van Wyk, B.E., Van Oudsho
 
 
 
 
 80
 
 
(2003) viewed on May 19, 2008, http://www.plantzafrica.com/plantqrs/sutherfrut.htm
59) Xaba, P., Notten, A. Sutherlandia frutescens (L.) R.Br. Kirstenbosch National Botanical Garden. 
. 
60) termination of 
vity of extracts obtained from Rosmarinus officinalis’ calli. 
Journal of Plant Physiology 164: 1536-1542 
 
Yesil-Celiktas, O., Nartop, P., Gurel, A., Bedir, E., Vardar-Sukan, F. (2007). De
phenolic content and antioxidant acti
 
 
 
 
 81
dix A1 
 
PRODUCTS 
List of selection criteria of solid dose Sutherlandia frutescens products  
le or tablet.   
2
300mg/dosage 
ould be no signs on the packaging label indicating the presence of other actives. Special note 
 to the effectiveness of the drug.   
kaging label.  
/Purchased at 
ld be clean and 
.    
5
ontainer choice of selection would be plastic securitainers with snap-on or screw-on caps.  The containers 
 This also 
eal) should be fully intact on all newly 
 tampered with.  
6
nsumer.  The products 
e present on the label.     
ent as this provides a record of the production history of the product.  The 
date indicates when the product is expected to have deteriorated.  No product is to be bought if the 
e conditions 
 in specific 
e, humidity and light.    
9. Popularity 
The number of a specific S. frutescens containing product on the shelves of various stores. 
10. Quantity  
At least one months supply (approximately 30) tablets or capsules should be available in each of the selected S. 
frutescens containing products.   
Appen
SELECTION CRITERIA OF SOLID DOSE SUTHERLANDIA FRUTESCENS
 
1. Solid dosage form 
The dosage form for the S. frutescens product selection should either be in the form of a capsu
. Composition 
The selected product must contain only Sutherlandia frutescens as a single active ingredient (90-
form). There sh
should be taken of the preservatives added to the product as these may contribute
3. Manufacturer 
The manufactures name as well as their contact details should be visible on the pac
4. Supplier
Note the appearance and location of the store where the product is to be purchased.  Store shou
product should be easy to locate on the shelf. Try to establish whether a supplier chain exists
. Packaging 
The c
should serve its function of protecting the product from deterioration by environmental conditions. 
allows for opening and resealing of the product.  A safety seal (tac s
purchased products to ensure that the product has not been
. Label 
The labeling should be clear and visible.  All printed information should be legible to the co
name, manufacturer and an expiratory date should also b
7. Batch number and expiratory date (manufacture date) 
The batch number should always be pres
expiratory 
expiratory date falls within the next 7 months of this year (2008).      
8. Storag
The storage conditions should be stipulated on the container, whether the product is to be stored
conditions, i.e. temperatur
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ndix A 
ANTIOXIDANT ACTIVITY OF UTHERLANDIA CONTAINING PRODUCTS 
 
Tab he per PPH g co ceti
etin at 492nm orbance at 540nm  
Appe
 
S
 
le A.1: T cent inhibition of D  by varyin ncentrations of quer n. 
Querc Absorbance Abs
(mg/ml)  after 
Inhibition 
0mins 
% Inhibition % 
30mins after 4
0.0000 0.615 0.0000 0.00000 0.7260 
1.0000 0.555 9.7561 12.53440 0.6350 
2.0000 0.555 9.7561 15.97800 0.6100 
5.0000 0.4680 23.9024 0.4610 36.5014
10.0000 0.2940 52.1951 0.2040 71.9008
 
Table The percent i by varyi concen c acid. 
c Acid Absorban m Ab e at 54
A.2: nhibition of DPPH ng trations of ascorbi
Ascorbi ce at 492n sorbanc 0nm  
(mg/ml)  after s 
nhibition 
0mins 
% Inhibition % I
 30min after 4
0.0000 0.478 0.0000 00000 0.4200 0.
0.0176 0.525 -9.8326 6.19050 0.4460 -
0.0352 0.4510 5.6485 0.4460 -6.1905
0.0880 0.3080 35.5649 0.3370 19.7619
0.1170 0.2410 49.5816 0.2800 33.3333
 0.1760 0.2050 57 0.2810 33.0952.1130 
 
 
 
 
 
 
 
 
 
 
Figure A.1:  Absorbance of DPPH after the addition of 200ul of various concentrations of quercetin.   
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Table A.7     Percent inhibition of 
Table A.4 Table A.5
Table A.6 Table A.8
Table A.9
Table A.3 
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ndix B 
 
 
 
 
 
 
 
igure B.1:  Gallic acid concentration versus absorbance at 690nm 
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UMID 
TY OF SCP 
AS DETERMINED BY DPPH AND FRAP ASSAYS 
Appendix C 
EFFECT OF AMBIENT AND ELEVATED TEMPERATURE AND H
ENVIRONMENTAL CONDITIONS ON THE ANTIOXIDANT ACTIVI
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Figure C.1:  The DPPH antioxidant activity of Sutherlandia containing products enduring the effect of elevated 
temperature and environmental humidity 
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aining products Table C.1:  Ferric reducing antioxidant power of stressed and unstressed Sutherlandia cont
Antioxidant activity (FRAP, ascorbic acid c equivalen e mg/ml)) 
Product 
  Control Ambient Climatic chamber STDEV Average RSD% 
1  Bio-Sutherlandia® 1.133789 1.209806 1.403648803 0.139151 1.24908 11.14025 
2  Sutherlandia SU1® 1.304827 1.042569 1.289623717 0.147222 1.21234 12.14363 
3  Health Wholefoods 
Connection 
Sutherlandia® 
1.456861 1.434055 1.624097301 0.103766 1.505 6.89472 
4   Pinnacle 
Sutherlandia® 
1.768529 1.72672 2.011782592 0.153938 1.83568 8.385885 
5  Promune® 4.664766 .630 79361  5 1.545409 4 559 4.52 46 0.071209 4.6077
6  Sutherlandia Pro® 1.464462 1.32003 2.327251995 0.544635 1.70391 31.96373 
7  Sutherlandia 350® 2.654124 2.011783 1.947168377 0.390846 2.20436 17.7306 
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ndix D 
 HUMID 
ENVIRONMENTAL CONDITIONS ON THE TOTAL PHENOL CONTENT OF 
SCP 
 
D.1:  Total phenol content of Sutherlandia containing products (SCP) after storage in original packaging in 
dark cupboard.  
 
Appe
 
EFFECT OF AMBIENT AND ELEVATED TEMPERATURE AND
 
Table 
Product Abs 1 Abs 2 Abs 3 mg GAE/ml 
1mg/ml 690nm 690nm 690nm 1 2 3 Average Stdev 
1 0.174 .231 0.24 24. 4.518 4.162 12.2790  8 986 3.001
2 0.233 .282 0.25 51 09 0.6520  6 .603 4.571 5.875 5.2
3 0.320 .253 0.22 78. 5.103 5.404 0.9550  0 220 6.887
4 0.341 .397 0.37 104. 8 79 0.7470  9 837 7.446 .936 8.2
5 0.540 0.650 0.564 131.454 12.742 15.670 13.930 1.473
6 0.279 0.278 0.271 158.071 5.795 5.769 5.715 0.041
7 0.278 0.385 184.688 5.609 5.769 6.637 0.5530.272 
 
 
Tabl .2:  tal ph onten therlan ntaining produc ) after s  for hs in ambient 
ditio
e D To enol c t of Su dia co ts (SCP torage 2 mont
con ns 
Product Abs 1 Abs 2 Abs 3 mg GAE/ml 
1mg/ml 690nm 690nm 690nm 1 2 3 Average Stdev 
1 0.277 .277 0.26 5 69 0.3490  1 .742 5.316 5.050 5.3
2 0.481 .481 0.45 11 11.891 11.153 0.7450  2 .172 10.400
3 7.845 0.7340.356 0.356 0.332 7.206 6.381 7.143
4 0.715 0.715 0.662 17.400 15.990 16.415 16.600 0.724
5 0.968 0.968 1.014 24.134 25.359 21.845 23.777 1.783
6 0.500 0.500 0.502 11.678 11.731 11.278 11.561 0.247
7 0.477 0.477 0.497 11.065 10.613 11.091 0.49311.598
 
 
Tabl .3:  tal ph onten therlan ntaining produc ) after  for 2  in elevated 
pera nd hu  condi
 
e D To enol c t of Su dia co ts (SCP storage  weeks
tem ture a midity tions. 
Product Abs 1 Abs 2 Abs 3 mg GAE/ml 
1mg/ml 690nm 690nm 690nm 1 2 3 Average Stdev 
1 0.155 .154 0.159 2. 2 21 0.0700  495 2.468 .601 2.5
2 0.182 0.187 0.191 3.213 3.347 3.453 3.337 0.120
3 0.210 0.214 0.217 3.959 4.065 4.145 4.056 0.093
4 0.241 0.240 0.249 4.784 4.757 4.997 4.845 0.131
5 0.359 0.464 0.447 7.925 10.719 10.267 9.636 1.500
6 0.304 0.297 0.310 6.461 6.274 6.620 6.451 0.173
7 0.243 0.261 0.256 4.837 5.316 5.183 5.112 0.247
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ndix E 
K PURITY 
PROFILES OF COLLECTED FRACTIONS OF SCP 
 
Appe
 
CHROMATOGRAPHIC FINGERPRINTS AND SPECTRAL AND PEA
 
 
Figure E.1: HPLC chromatogram (A), and spectral absorbance (B) and purity (C) profiles of collected fraction 
1, with peak at retention time of 10.928 minutes.   
 
 
  
 
 
A 
C 
Figure E.2: HPLC chromatogram (A), and spectral absorbance (B) and purity (C) profiles of collected 
fraction 2, with peak at retention time of 11.969 minutes.   
 
A 
B C 
B 
 
 
 
 
 
Figure E.3: HPLC chromatogram (A), and spectral absorbance (B) and purity (C) profiles of collected 
fraction 3, with peak at retention time of 14.373 minutes.   
 
 
 
 89
Figure E.4:  HPLC chromatogram (A), and spectral absorbance (B) and purity (C) profile llected 
fraction 4, with peak at retention time of 15.040 minutes. 
 
 
 
 
s of co
 
Figure E.5: HPLC chromatogram (A), and spectral absorbance (B) and purity (C) profiles of collected 
fraction 5, with peak at retention time of 18.022 minutes. 
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ndix F 
COLLECTED FRACTIONS 
 
Appe
 
CHROMATOGRAPHIC FINGERPRINTS AND LCMS DATA OF HPLC 
      
 
 
 
Figure F.1and F.2:   Chromatographic fingerprint and LCMS data of fraction 1 (retention time = 10.928min) 
collected by HPLC (see fig. E.1). 
 
 
 
 
 
Figure F.3 and F.4: Chromatographic fingerprint and LCMS data of fraction 1 (retention time = 11.969min) 
collected by HPLC (see fig. E.2). 
        
 
 
           
Figure F.5 and F.6: Chromatographic fingerprint and LCMS data of fraction 1 (retention time = 14.373min) 
collected by HPLC (see fig. E.3).
 
 
 
Figure F.7 and F.8: Chromatographic fingerprint and LCMS data of fraction 1 (retention time = 15.040min) 
collected by HPLC (see fig. E.4). 
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ndix G 
CP 
 
 
Appe
 
CHROMATOGRAPHIC FINGERPRINTS OF AMBIENT STORED S
 
Figure G.1:  Chromatogram of ambient stressed Sutherlandia containing product 1. 
 
 
 
 
Figure G.2: Chromatogram of ambient stressed Sutherlandia containing product 2. 
 
 
 
Figure G.3: Chromatogram of ambient stressed Sutherlandia containing product 3. 
 
 
 
 
 
Figure G.4: Chromatogram of ambient stressed Sutherlandia containing product 4. 
 
 
 
Figure G.5: Chromatogram of ambient stressed Sutherlandia containing product 5. 
 
 
 
Figure G.6: Chromatogram of ambient stressed Sutherlandia containing product 6. 
 
 
Figure G.7: Chromatogram of ambient stressed Sutherlandia containing product 7. 
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ndix H 
SCP 
 
Appe
 
CHROMATOGRAPHIC FINGERPRINTS OF CLIMATIC CHAMBER STORED 
 
Figure H.1: Chromatogram of climatic chamber stressed Sutherlandia containing product 1. 
 
 
 
Figure H.2: Chromatogram of climatic chamber stressed Sutherlandia containing product 2. 
 
 
 
 Figure H.3: Chromatogram of climatic chamber stressed Sutherlandia containing product 3. 
 
 
 
 
 
Figure H.4: Chromatogram of climatic chamber stressed Sutherlandia containing product 4. 
 
 
 
Figure H.5: Chromatogram of climatic chamber stressed Sutherlandia containing product 5. 
 
 
 
Figure H.6: Chromatogram of climatic chamber stressed Sutherlandia containing product 6. 
 
 
Figure H.7: Chromatogram of climatic chamber stressed Sutherlandia containing product 7. 
 
 
 
 94
 
 
 
 
 95
ndix I 
NMENTAL 
STORAGE CONDITIONS  
 
Table I.1  solid dose products’ sutherlandins after a period of storage in 
elevated tem viron .  
Appe
 
TABLE OF PEAK HEIGHT VALUES AFTER DIFFERENT ENVIRO
 
:  Difference in peak heights of Sutherlandia
perature and en mental humidity
Sutherlandin A Sutherlandin B Sutherlandin C Sutherlandin D 
Product 
Am
Climatic 
ch
Am
Climatic 
c er
bient
Climatic 
am
Ambient
Climatic 
chamber 
bient 
amber
bient
hamb  
Am
ch ber 
1 Bio-Sutherlandia® 94.4 78. 75 .8 2.1 116 97.2 8 90 .4 193 16  
2 Sutherlandia SU1® 5 100 82 .3 75.5  4 .7  25.9 .6 39 140  18.5 
3 Health Wholefoods 
Connection 
Sutherlandia® 
0 102 .2 10 .7 .4 136.1 134.6 1 7.4 .9 106 6.5 215 212  
4 Pinnacle Sutherlandia® 147.8 143.8 96.9 96 245.9 236.1 109.5 102 
5 Promune® 26 194 24 6.3 .2 165.8 6.5 .6 335.5 7.5 22 170  217.1 
6 Sutherlandia Pro®  12 4 12.5 27.1 - 19.7  7.8 17.7 6.
7 Sutherlandia 350® 272.4 234.1 211 182.4 358.5 329 201.4 179.6 
P values  0.0136 0.0072 0.0283 0.0190 0.0309 0.0230 0.0418 0.0240 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
